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1. Introduction 
The great time of deoxyribonucleic acid, commonly known as DNA, has passed. DNA 
was a celebrity decades ago, when Watson and Crick were the first to predict the double-
helical nature of DNA (1953) or when Meselson and Stahl discovered the mechanism of 
DNA replication (1958). Even the first knock-out mouse was born nearly twenty years 
ago. DNA is old-fashioned. Today, ribonucleic acid (RNA) is everything. RNA is thought 
to have played around on Earth before everything else existed. It is still there and full of 
surprises: the discovery of a very short and special type of RNA in the late 1990ies has led 
to a paradigm shift in biology about the knowledge on how gene expression is regulated. 
The Central Dogma of molecular biology again had to be revised.  
1.1 The Central Dogma 
Originally, the Central Dogma was formulated by F. Crick1. In his paper from 1958 “On 
Protein Synthesis”, he discussed the direction of information flow in the cell.  
With DNA, RNA, and protein being the three corners of 
a triangle he explained three types of transfers existing 
between them (Figure 1): “unlikely” transfers from 
proteins to nucleic acids, “possible” transfers from RNA 
to DNA or DNA to proteins, and “known” transfers from 
DNA to RNA to proteins.  
Although the Central Dogma as proclaimed by Crick 
neither excluded a reverse flow of information from 
RNA to DNA nor stated that the flow of information 
always stops at protein level it was interpreted in a more 
restrictive way: the conventional Central Dogma of 
molecular biology defines the information flow from 
storage (DNA) to effectors (proteins), i.e. that DNA 
makes RNA and RNA makes protein, and most 
importantly that this flow is not reversible. In this scheme, RNA was considered only as 
an intermediate in the flow of information.  
 
Figure 1: Crick wrote about this 
scheme: “Solid arrows represent 
probable transfers, dotted arrows 
possible transfers. The absent arrows 
represent the impossible transfers 
postulated by the central dogma. 
They are the three possible arrows 
starting from proteins.” Adapted 
from Thieffry, 19981. 
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The conventional view of the dogma was later challenged by the findings that RNAs can 
act as enzymes or “ribozymes”, by the discovery of retroviruses, alternative splicing, 
mRNA editing, and prions1. All these phenomena did not fit into the conventional idea of 
DNA being the only source of hereditary information and the announcement of a pre-
historic “RNA World” provided further support to the view that RNA is more important 
than previously thought.  
1.2 RNA World: The Molecular Biologists’ Dream 
When two independent research groups discovered a new role of RNA in the 1980s2, 
showing that this molecule is not only an intermediate in the flow of genetic information, 
but also able to take over enzymatic functions (ribozyme), the idea of self-replicating 
systems at the origin of life consisting only of RNA evolved. W. Gilbert was the first to 
propose the existence of an “RNA World” in 1989, picturing a hypothetical stage in the 
origin of life preceding the DNA/RNA/protein world3. The idea of an RNA World 
would resolve the “chicken and egg problem” of which came first, nucleic acids or 
proteins, as RNA alone combines informational and catalytic roles previously splitted 
between RNA and proteins.  
The “Molecular Biologists’ Dream” was a term coined by Joyce & Orgel in 1999 to 
describe the origin of the RNA World based on extrapolations of the findings of prebiotic 
chemists4. They proposed that nucleotides were formed by prebiotic reactions on Earth 
from nucleosides and sugars and combined to polynucleotides with the help of a mineral 
catalyst. Then, after double-strand RNAs were generated by template-directed synthesis, 
at least one of these RNAs melted and gave rise to a ribozyme, an enzymatically active 
RNA, which started copying itself and its complement. The “Molecular Biologists’ 
Dream” suggests that life descends from only one or a few RNA molecules that started 
replication of polynucleotides four billion years ago. However, this dream is mere 
speculation and other hypotheses on the origin of life exist as well, which try to 
circumvent the problems of an RNA World, namely that the issue of RNA stability and 
synthesis remain implausible. In the “pre-RNA World”, an RNA-like polymer is proposed 
which possesses the catalytic and templating functions of RNA and is easily replicated5. 
Nevertheless, current opinion in biology holds that RNA did not only play a major role at 
the origin of life (either at the beginning or after the pre-RNA World) but is also one of 
the key players in complex organisms of today6. For the journal “Science” latest 
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discoveries of RNA function were nominated as the “2002’ Breakthrough of the Year”, 
for the Nobel Foundation it was even more: in 2006 two researchers were awarded the 
Nobel Prize in medicine for their findings in gene regulation by small RNAs. 
1.3 Small RNAs 
1.3.1 Beginnings of RNA Silencing: when flowers turned pale 
First hints that a novel layer of genetic regulation was waiting to be deciphered emerged 
in 1990, when Napoli and colleagues generated transgenic petunia flowers by introducing 
an additional gene copy for the pigment synthesis enzyme chalcone synthase7, 8. Aiming at 
an enhanced coloration of the petals, they unexpectedly yielded flowers with pigmentation 
patterns or even completely white petals (Figure 2).  
This phenomenon was termed “co-
suppression” or “post-transcriptional gene 
silencing” (PTGS), as the introduced gene 
copy did not enhance, but blocked the 
expression of the endogenous gene, 
leading to the loss of coloration due to the 
lack of the pigmentation enzyme in plant 
cells transfected with the gene copy.  
In the following years more and more 
studies in different organisms from fungi 
to flies showed that the introduction of 
DNA or RNA sequences from a cellular 
gene into cells resulted in down-regulation 
of the corresponding mRNA9. However, 
insights into the mechanism did not 
arouse until 1998, when Craig Mello and 
Andrew Fire identified double-stranded 
RNA (dsRNA) to be the PTGS-inducing agent10. In their experiments they demonstrated 
that introduction of unc-22 dsRNA into C. elegans resulted in a more effective down-
regulation of unc-22 mRNA than injecting only sense or antisense strands of the same 
RNA. Based on this and other observations, Fire and Mello could rule out the formerly 
 
Figure 2: Phenotypes of transgenic petunia flowers 
(Napoli 1999). A normal phenotype of petunia flowers 
is depicted on top. Each row shows four flowers from a 
single transgenic plant displaying the variety of petal 
patterns found on an individual petunia plant. 
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proposed antisense mechanism, which would suggest the formation of a hybrid RNA 
duplex between the introduced strand and the endogenous mRNA, leading to a block in 
translation. Shortly thereafter, Hamilton and Baulcombe provided additional evidence by 
their discovery of a correlation between PTGS and the presence of ~25-nucleotide (nt) 
antisense RNAs11. These small interfering RNAs (siRNAs) were complementary to target 
mRNAs and were never detected in the absence of PTGS, indicating a direct role in this 
mechanism. When Tuschl and colleagues demonstrated that chemically synthesized 
siRNAs were able to guide cleavage of their target mRNAs, a new era of gene silencing in 
mammalian cells was at the start12, 13. What followed next was a series of biochemistry 
work unveiling main actors in RNA silencing or RNA interference (RNAi): identification 
of Dicer as the dsRNA-siRNA converting enzyme14, purification of RISC, the complex 
mediating cleavage of target mRNA15, and identification of Ago2 as the protein factor 
with “Slicer” activity in RISC16, 17. Today it is known from both genetic and biochemical 
studies that the pathways underlying RNAi and factors involved exist in many eukaryotic 
organisms18. 
1.3.2 The RNAi pathway 
RNAi is triggered by an RNase III-like enzyme termed Dicer, which cleaves long dsRNA 
into ~21-nt short interfering RNAs (siRNAs) with 2-nt 3’ overhanging ends and 
phosphorylated 5’ ends19. dsRNAs derive from exogenous sources like viruses or internal 
aberrant transcription of repetitive sequences. The siRNA duplexes are incorporated into 
a protein complex comprising Argonaute (Ago) proteins where one of the strands is 
removed (“passenger” strand). The Argonaute effector complex is guided by its remaining 
siRNA strand (“guide”) to the target mRNA, where a single phosphodiester bond is 
cleaved between nucleotide position 10 and 11 counting from the 5’ end of the siRNA 
guide19, 20. Figure 3 shows a diagram of the siRNA pathway. 
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Figure 3: RNA silencing pathways. Left: siRNA pathway. siRNAs derive from dsRNA cleaved by Dicer and 
target RISC to the corresponding mRNA, resulting in cleavage and subsequent degradation of the mRNA. 
Right: miRNA pathway. miRNAs are transcribed from miRNA-encoding genes, cleaved by Drosha in the 
nucleus and exported into the cytoplasm, where they are procsessed by Dicer into functional and mature 
miRNAs. They guide RISC or miRNP to their target mRNA and induce repression of translation or mRNA 
decay. For details, see text. Figure adapted from Großhans, 2008. 
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1.3.3 Small RNAs now and then 
siRNAs represented a completely though artificial new type of small RNAs. However, 
they were neither the first nor the last discovered. Members of the small RNA species 
were already found in the 1960ies in the nuclei and shortly after in the cytoplasm of 
mammalian cells21, 22. At that time, small RNAs were RNA molecules not directly 
involved in protein synthesis and sized only between 90-300 nt23. Later, small RNAs were 
also discovered in prokaryotes to be involved in regulatory and synthetic functions, e.g. 
control of gene expression, plasmid copy number, peptidoglycan synthesis, and phage 
DNA packing24.  
Today it is estimated that about 98% of transcribed genes in humans consists of small or 
non-coding RNAs25. Although proteins were always considered to be the cellular effectors 
and main regulators of transcription, the discovery of a new class of small RNAs in a 
seemingly small and insignificant organism, a worm, was influential in proposing that this 
type of RNA may account for the complexity and phenotypic variation of higher 
organisms25.  
1.4 microRNAs - A new class of small RNAs 
Lin-4 was a small RNA identified in 1993 as a temporal regulator in the development of 
the worm Caenorhabditis elegans26, 27, followed by let-7 in 200028. In the same year, let-7 was 
found to be conserved in a wide range of animal species, leading to the introduction of the 
term “small temporal RNAs” (stRNA) for the newly discovered short, non-coding 
RNAs29. The existence of additional stRNAs involved in developmental control was 
proposed at the same time29. Only one year later, several groups announced the discovery 
of many more stRNAs in various organisms, which were from now on termed 
microRNAs30-32.  
Today, the term microRNA (miRNA) describes a class of small non-coding, single-
stranded RNA molecules possessing a crucial regulatory function in diverse biological 
processes18, 20, 33. They are encoded by either specific genes (exons), in intergenic regions 
or in introns of protein-coding genes34. After transcription and several processing steps a 
19-24 nt single-stranded RNA stretch is formed which is incorporated into an effector 
complex. Nowadays, hundreds of miRNAs in plants, worms, flies, mammals and even 
viruses in various tissues and organs are known. Their function is not restricted to 
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development, but they are involved in many regulatory pathways. In humans, more than 
600 miRNAs have been sequenced according to the miRBase Sequence Database 
(http://miRNA.sanger.ac.uk), predicted to regulate the expression of more than 30% of 
the genes in the human genome35. In the last few years, miRNAs have been shown to play 
pivotal roles in controlling cell differentiation, proliferation and apoptosis both in native 
and disease conditions33, 36. Although the pace of progress in elaborating the nature of 
RNA silencing is overwhelming, many details on biology, mechanism and targets of 
miRNAs remain to be uncovered18, 33.  
1.5 miRNA Biogenesis 
Like any other family of cellular RNAs, the origin of miRNAs resides in the genome. 
From here, they are transcribed by RNA polymerase II or III in mono- or polycistronic 
fashion, often being several kilobases long33. These transcripts, named primary miRNAs 
(pri-miRNAs) display features of common mRNAs like a m7G-cap and a poly-A-tail to 
prevent immediate degradation. Still in the nucleus, an RNase III enzyme called Drosha 
assisted by the RNA-binding protein Pasha/DGCR8 cleaves the pri-miRNAs. The 
cleavage product, a ~ 70 nt long miRNA precursor (pre-miRNA) with a 2-nt 3’ overhang, 
is transported into the cytoplasm through the nuclear pores with the aid of exportin-5. 
The export of pre-miRNAs into the cytoplasm allows the second processing step to take 
place, which resembles in many ways the siRNA pathway. The second step, also termed 
maturation step, is catalysed by Dicer in complex with Loquacious (TRBP in mammals) 
and results in a 19-24 nt long duplex with again a 2-nt 3’ overhang. Similar to siRNAs, 
the miRNA duplex is incorporated into an effector complex termed RNA-induced 
silencing complex (RISC) or miRNP for miRNA-ribonucleoprotein. The main 
components of RISC are proteins of the Argonaute (Ago) family, which bind the mature 
miRNA via their PAZ domain. In humans, there are 4 Ago proteins (Ago1-4). Several 
assembly and regulatory proteins associated to the complex have also been identified. 
Only one strand of the duplex, the “guide” strand, remains bound to RISC, while the 
other (“passenger” strand) is removed. The preference for one strand lies in the 
thermodynamic stability of the duplex ends: the strand with the thermodynamically least 
stable 5’ end remains in the complex. The strand bound to RISC guides the effector 
complex to the target mRNA and thereby blocks translation or induces degradation. 
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1.6 Mode of (inter)action 
miRNAs control gene expression by blocking translation or promoting mRNA 
degradation in a sequence-specific manner18, 37. In plants, they bind their target mRNA 
almost perfectly, thereby inducing endonucleolytic mRNA cleavage followed by 
degradation. Metazoan miRNAs require perfect complementarity to the miRNA target 
site only for the nucleotides at position 2-8, referred to as the “seed” region35. Precise 
binding of this heptamer to mRNA target sites in the 3’-untranslated region (3- UTR) is 
sufficient for miRNA functioning. However, additional features in the central or 3’ region 
of the miRNA improve silencing efficacy37. An unpaired region, called “bulge”, is 
characteristic for miRNAs in contrast to siRNAs. 
The regulatory potential of miRNAs 
lies in their ability to influence the 
pattern of gene expression. miRNAs 
have been shown to play a role in 
mRNA decay, inhibition and 
sometimes even stimulation of 
translation18. The most common mode of action employed by miRNAs is the repression 
of target mRNA translation. Nevertheless, controversy exists about the exact mechanism. 
Four different ways of repressing translation have been published until now: co-
translational protein degradation, inhibition of translation elongation, premature 
termination of translation, and inhibition of translation initiation38 (Figure 5).  
It has remained elusive at which step miRNAs interfere with translation. Established 
methods like examining polysome-bound mRNAs in sucrose gradients have resulted in 
contradicting interpretations of the silencing mechanism39-41. Furthermore, experiments 
demonstrating a cap-dependent repression illustrate a convincing mechanism, 
nevertheless it was shown as well that silencing occurs in a cap-independent way40-42. 
Experimental evidence for each of the possibilities has been provided, resulting in an 
ongoing debate whether the dispute arises from different experimental approaches and 
interpretations thereof or reflects the diversity of miRNA silencing mechanisms.  
The influence of miRNAs in mRNA decay is known in more detail. By imperfectly 
binding to the target site, miRNAs induce removal of the 3’ poly(A) tail from the mRNA, 
resulting in 5’ decapping and subsequent exonucleolytic digestion starting from the 5’ end. 
 
Figure 4: miRNA-mRNA interaction. Metazoan miRNAs 
basepair with their target sequence in the 3’ UTR of 
mRNAs imperfectly. Precise complementarity is only 
required for the “seed” region (depicted in dark red).  
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The individual contribution of mRNA destabilization and translational repression, 
respectively, differs from one mRNA to another18. Figure 5 gives an overview on the 
published mechanisms of miRNA action including different proposed mechanisms of 
translational repression. 
 
Figure 5: Mechanisms of miRNA action. (A) Postinitiation mechanism.  
miRNAs block translational elongation. (B) Co-translational protein 
degradation. In this model, translation is not inhibited, but the translated 
nascent polypaptide is degraded immediately. (C-E) Initiation mechanisms. 
miRNAs inhibit translation at an early step, so that elongation cannot take 
place. (F) mRNA decay. Bound miRNAs induce deadenylation and decapping 
of the target mRNA. Adapted from Eulalio, 2008. 
1.7 Regulation of miRNA expression 
When the first two miRNAs, lin-4 and let-7, were discovered, they were also found to be 
developmentally regulated26, 28. A loss of let-7 led to the recurrence of larval cell fates 
during adult stages, while increased let-7 levels induced the expression of adult fates 
during larval stages. Developmental timing of miRNA expression or tissue-specific 
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expression patterns was subsequently detected for many vertebrate miRNAs43. The 
majority of differentially regulated miRNAs may be due to regulation on transcriptional 
level as most miRNAs are transcribed in an RNA Polymerase II-dependent way33. 
However, several studies indicate that post-transcriptional regulation of 
miRNAsexpression might also contribute to the timing- or tissue-specific miRNA pattern. 
One example is miR-38 in C. elegans, where a post-embryonic down-regulation of the 
mature miRNA occurs, while the precursor miRNA is expressed throughout all stages 
from larval to adult worms44. This observation suggested an inhibition of miRNA 
maturation either by intervening in nuclear export or by directly blocking the accessibility 
of Dicer or the precursor33.  
Differential accumulation of precursor or mature miRNA was also found in rats 
engineered to overexpress individual miRNAs45, indicating a post-transcriptional 
regulation of processing efficiency. Another study showed differential regulation in 
cancerous versus normal colorectal tissue of human samples46, followed by a recent study 
in different tissues, tumors, and cancer cell lines revealing widespread discrepancy 
between the levels of precursor and mature miRNA47. Examining expression patterns of 
miRNAs in zebrafish brains, Kapsimali et al. also supported the idea of a post-
transcriptional regulation, as they found that miRNAs transcribed from the same cluster 
nevertheless display differential expression48. 
In general, regulation of miRNA expression may occur at different levels: inhibition of 
Drosha processing, prevention of nuclear export, or blocking of Dicer processing. 
Thomson and colleagues showed that a large fraction of miRNAs in mouse is down-
regulated post-transcriptionally at the Drosha processing step49. Last year, Guil and 
Cáceres were the first to identify a protein factor involved in regulation of miRNA 
biogenesis50. They could show that the RNA binding protein hnRNP A1 was essential 
during Drosha processing of pri-miR-18a. RNAi-based depletion of the auxiliary protein 
factor resulted in reduction of in vitro processing activity and decreased levels of pre-miR-
18. Control experiments revealed that the effect of hnRNP A1 on processing was specific 
for pri-miR-18a, supporting the idea that individual miRNAs require specific cofactors 
during biogenesis. SMAD proteins were also found to play an auxiliary role in Drosha 
processing of pri-miR-2151.  
First preliminary insights into mechanistic details of regulation of Drosha processing were 
provided by two independent research groups: this year, the labs of Gregory and 
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Hammond demonstrated that lin-28 selectively blocks miRNA processing at the Drosha 
step by binding to conserved nucleotides in the loop region of pri-let-752-54. More studies 
concerning let-7 processing by lin-28 or regulation of Drosha in general can be envisioned 
in the near future. 
1.8 Background of this Thesis 
To understand the complex regulatory networks of miRNAs which involves the regulation 
of one mRNA target by many miRNAs, and the control of several targets by a single 
miRNA, regulation of miRNA expression needs to be investigated55. Several research 
groups have demonstrated regulation of Drosha processing by various factors49-51 (see 
section 1.7 for more details). Nevertheless, the exact mechanism of regulation remains 
largely mysterious. 
However, control of miRNA biogenesis at other steps than Drosha processing is even less 
understood. Wulczyn showed that let-7 processing is inhibited at the precursor level in 
undifferentiated EC cells56. Some progress has been made recently, when Rybak and 
colleagues identified lin-28 to be an inhibitor of pre-let-7 Dicer processing, challenging 
previous work from Hammond and Gregory labs57 (see section 1.7). However, Rybak 
explained the discrepancy in results by a multi-level post-transcriptional control of let-7 
expression, involving inhibition at Drosha and Dicer processing in parallel.  
Regulation of miRNA biogenesis at Dicer level is also subject of ongoing research in the 
Martinez Lab58-60. In 2006, Obernosterer et al. used Northern blots and in situ 
hybridizations to demonstrate that the precursor of the brain-specific miRNA miR-138 is 
ubiquitously found in mouse, whereas the mature transcript is restricted to neurons of the 
neo-cortex, the hippocampus, the cerebellum, and to cells of the fetal liver60. Thus, an 
additional layer of miRNA regulation besides the regulation on promoter level was 
proposed. Using in vitro processing assays, they provided evidence for the presence of a 
proteinaceous inhibitory factor in cells not expressing miR-138, ruling out the possibility 
of a Dicer activator.  
In later studies, Martinez et al. used mutation analyses to reveal the importance of the 
secondary structure of pre-miR-138 for recognition by the inhibitor. The structure of pre-
miR-138 includes a 2-nt overhang at the 5’ end, two central loops, a one-nucleotide bulge 
and a terminal loop (Figure 6). Dicer cleaves 5’ of or within the second loop, resulting in a 
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23 or 24 nt long mature miR-138. Closing loop 1 (Figure 6) by site-directed mutagenesis 
resulted in the recovery of Dicer processing activity in HeLa cell extracts indicating that 
the inhibitory effect is mediated via recognition of loop 158. 
 
Figure 6: Secondary structure of pre-miR-138. Top: The 69 nt long precursor 
comprises two central and one terminal loop and a single mismatch close to 
the terminal loop. Down: structure of mutated pre-miR-138, where loop 1 
was closed. Figure adapted from Leuschner, 2007.  
1.9 Aim of this Thesis 
In an effort to purify and identify the unknown inhibitor, a combination of classical 
chromatography and affinity purification had been employed58. The classical 
chromatography approach involved seven purification steps using various resins and 
elution conditions, yielding large numbers of putative inhibitors after mass-spectrometry 
analysis. A second, independent affinity purification approach using StreptoTag 
technology61 was employed in parallel to minimize the amount of candidate proteins co-
eluting with the inhibitory activity.  
Comparing mass-spectrometry and size analysis results from the classical purification 
series with data from the affinity chromatography approach revealed that a single protein 
of approximately the correct size as determined by gel filtration (15-20 kDa) appeared in 
both independent data sets. The protein found in both mass-spectrometry analyses was 
signal recognition particle 14 (SRP14).  
SRP14 is a highly conserved cytoplasmic ribonucleoprotein with a function in sorting 
secretory and membrane proteins to the endoplasmic reticulum as part of the SRP (signal 
recognition particle) complex62. SRP recognizes signal sequences on nascent polypeptide 
chains, resulting in an arrest of protein synthesis. The ribosome-SRP complex is then 
directed to the endoplasmic reticulum to the SRP receptor, where SRP dissociates from 
the ribosome and protein synthesis is continued with the simultaneous translocation of the 
emerging polypeptide into the endoplasmic reticulum.  
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SRP consists of six protein cofactors and a single 300-nt RNA molecule63 (Figure 7). Two 
of these polypeptides, SRP9 and SRP14, form a stable heterodimer in vitro and only then 
bind to a specific 87-nt long RNA sequence called Alu region64. 
As SRP9/14 can exist as a 
heterodimer without SRP, the 
possibility exists that it might play 
additional roles by forming 
complexes with Alu-like RNAs or 
even different small RNAs65. 
Furthermore, SRP9 and SRP14 
accumulate in 20-fold excess over 
SRP in primate cells as RNA-
bound complex or in free 
cytoplasmic form. Due to the 
RNA binding capability, the 
proposed additional roles of 
SRP9/14 heterodimer, and its 
excess over SRP, it constituted an 
interesting candidate to test for 
the putative inhibitory function in 
miRNA biogenesis. To examine a 
possible inhibitory role of the heterodimer SRP9/14 in Dicer processing, recombinant 
expression of this candidate protein together with its binding partner SRP9 as well as 
RNAi-mediated knock-down in HeLa cells was performed, followed by testing of the 
depleted extract and the recombinant protein, respectively, on Dicer in in vitro processing 
assays. 
 
 
 
Figure 7: Structure of SRP. (Top) Molecular model of SRP. Cyan, 
blue and grey: SRP proteins; red and yellow: 7S RNA; green: 
signal sequence. Adapted from Halic, 2005. (Bottom) Schematic 
representation of SRP. Proteins are shown in colored and grey 
ovals, RNA is depicted in orange. SRP9 and SRP14 form a 
heterodimer and bind to the Alu Subunit of SRP. Adapted from 
Maity, 2007. 
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2. Results 
Two approaches were employed in order to test the role of SRP9/14 in miRNA 
processing as a putative candidate protein for the inhibition of miRNA maturation. 
a) Recombinant expression of SRP9 and SRP14 in bacteria, 
b) Knockdown of SRP9 and SRP14 in HeLa cells by means of RNA interference. 
First, recombinant expression allowed the addition of SRP9 and SRP14 to the already 
established in vitro processing assays of pre-miR-138. Inhibition of in vitro pre-miRNA 
processing using recombinant protein would provide evidence for SRP9/14 being a valid 
candidate. 
In the second part, the aim of investigation was whether SRP9/14-depleted HeLa cell 
extracts would be able to process pre-miR-138. Recovery of processing activity would 
indicate that SRP14 alone or in complex with SRP9 is indeed involved in inhibition of 
Dicer. 
2.1 Recombinant Expression of SRP14 
2.1.1 Cloning of SRP9 and SRP14 
One approach to test a potential candidate for its putative function is its recombinant 
expression and subsequent addition to the functional test. To express a recombinant 
protein, the gene of interest needs to be inserted into a vector specialized for expression, 
like pDEST17 which contains a T7 promoter for IPTG-inducible transcription. Thus, the 
first aim was to insert human SRP9 and SRP14 genes into the bacterial expression vector. 
For cloning, the Gateway® Technology developed by Invitrogen was chosen (see 
Methods section 5.8.1).  
SRP9 and SRP14 were amplified from the RIKEN clone 9530033C02 (261 bp) and 
F830102009 (333 bp), respectively. Using Gateway® Technology, universal attB-sites 
were added to the 5’ and 3’ ends of the cloned gene. attB sites serve as recombination sites 
to insert the attached gene into a pDONR vector (pDONR201), which again contains 
recombination sites to shuttle the gene of interest into an optional destination vector. For 
the purpose of this thesis, pDEST17 was used as destination vector (Figure 8). Final 
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sequencing analysis revealed that the SRP9 and SRP14, respectively, were successfully 
cloned into pDEST17.  
 
 
Figure 8: (A) pDONR201 vector map. (B) pDEST17 vector map. 
pDEST17 contains an ampicillin resistance gene and a coding 
sequence for a N-terminal His-tag. SRP9 and SRP14 were inserted 
after the His-tag via recombination, replacing the chloramphenicol 
resistance and the ccdB gene, the latter one preventing cells from 
growing on culture. Adapted from Invitrogen. 
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pDEST17-SRP9 and pDEST17-SRP14 were then used for bacterial expression of His-
tagged SRP9 and SRP14. 
2.1.2 Expression and purification of SRP9 and SRP14 
pDEST17-SRP9 and pDEST17-SRP14 were transformed in chemically competent E. coli 
(RosettaTM) and expressed overnight upon IPTG induction (see “Methods”, section 5.6.1, 
for details). After bacterial lysis, His-tagged SRP9 and SRP14 were purified using Ni-
column affinity chromatography. During the purification, aliquots of each step were taken 
and loaded on a polyacrylamide gel to check for enrichment of the recombinant protein.  
Figure 9A shows a Coomassie stain with aliquots from SRP9 purification. Surprisingly, 
the band emerging after induction of protein expression was detected between 10 kDa 
and 15 kDa., exceeding the expected 9 kDa for SRP9 slightly. Pellet and input both 
comprised similar levels of SRP9, indicating that the bacterial lysate contained only half of 
total protein. The flow-through was devoid of SRP9, implying that the column was not 
overloaded. During the washing steps, some of the protein was eluted probably due to 
increasing concentrations of imidazole in all of the wash buffers (25-100 mM). 
Nevertheless, the majority of protein was eluted with 300 mM in elutions 1 and 2.  
Figure 9B shows a Coomassie-stained gel from SRP14 purification. A band at 15 kDa 
existing in the induced aliquot but not in the uninduced sample indicated that SRP14 
expression was successfully initiated upon adding IPTG to the medium. Due to overload 
of the third lane (pellet), it cannot be clarified, whether the majority of the recombinant 
protein remained in the pellet or in the supernatant after bacterial lysis. The flow-through 
still contained a large amount of SRP14, indicating that the Ni-column was oversaturated. 
The concentration of imidazole was increased during the four washing steps (25-100 
mM), which might be responsible for partially elution of bound SRP14 with washing 
buffer. Similar to purification of SRP9, the majority of the protein was eluted with 300 
mM imidazole in elution 1 and 2. 
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Figure 9: (A) Purification of SRP9 on Ni-column. 45 µg of cell lysate or protein was loaded per sample 
well. The Coomassie stain shows that upon IPTG induction, SRP9 was expressed (lane “Uninduced” vs. 
lane “Induced”). Enrichment of SRP14 was successful in eluate 1 and 2 (300 mM imidazole), although 
the samples were contaminated with various proteins. (B) Purification of SRP14 on Ni-column. 45 µg of 
cell extract or protein was loaded per sample well. Expression of SRP14 was induced with IPTG. His-
tagged SRP14 was purified on Ni-column and eluted at 300 mM imidazole in elution 1 and 2. 
2.1.3 Analysis of recombinant SRP9/14 in processing assay 
The processing assay was performed using radiolabeled pre-miR-138, recombinant Dicer 
enzyme (rDcr) and dialyzed recombinant SRP9/14. Results indicated that only the 
addition of undiluted SRP9/14 resulted in inhibition of processing in the in vitro assay, but 
not diluted SRP9/14 (1:5, 1:10, 1:50, 1:100). pre-miR-19 and pre-miR-138L1, a mutated 
variant of pre-miR-138 (see also Figure 6) served as control substrates. Contrary to pre-
miR-138, pre-miR-138L1 displays no inhibition of processing by HeLa cell extracts due 
to the closing of loop 1. The inhibitory effect of undiluted SRP9/14 was observed with 
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both pre-miR-138 and pre-miR-138L1, indicating that this effect is not specific for pre-
miR-138 but due to unspecific binding of SRP9/14 to RNA (Figure 10). Inhibition of 
Dicer processing after addition of recombinant protein might be due to an unspecific 
RNA binding by SRP9/14, blocking the access of Dicer to the precursors. 
 
 
Figure 10: Dicer in vitro processing assay with SRP9/14. 5 µl of the reaction mix were 
loaded per sample well. Incubation of pre-miR-138 with SRP9/14 and Dicer resulted in a 
reduction of mature miRNA in the undiluted SRP9/14 sample. The same effect was detected 
when incubating with control pre-miR-138L1, indicating that an unspecific RNA binding 
effect of SRP9/14 resulted to inhibition of processing by Dicer. The usually included control 
pre-miR-19 did not work in all assays involving SRP9/14, as can be seen here in the left-
most set of bands. 
2.1.4 Cloning of the fusion protein SRP9-myc-SRP14 
One explanation why SRP9 and SRP14 did not show the expected effect of inhibition 
was the possibility that SRP9 and SRP14 could not form the heterodimer required to 
bind RNA properly due to unequal molarities of both proteins. For example, SRP9 and 
SRP14 do not bind to Alu sequences as monomers66. As it seemed to be difficult to 
simulate the native conditions under which formation of the SRP9/14 complex was 
facilitated, a different strategy was employed. A fusion protein of SRP9 and SRP14 linked 
by a myc epitope has been shown to fulfill the biological function of the heterodimer, i.e. 
binding to Alu RNA66. Generation of this fusion protein would resolve problems of 
unequal protein molarity. 
The fusion protein SRP9-myc-14 consisted of the SRP9 protein fused at its C-terminus to 
a myc-tag (-EQKLISEED), which was linked to the N-terminus of SRP14 (Figure 11). 
SRP14 followed by myc epitope and SRP9 has been shown to be functional as well66, but 
generation of this permutation was not pursued here.  
Preparing the constructs for the fusion protein was more complicated than cloning the 
individual recombinant proteins. A short linker sequence comprising 51 nucleotides (myc-
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tag) had to be inserted between the 3’ end of the SRP9 gene (srp9, 261 bp) and the 5’ end 
of  
SRP14 gene (srp14, 333 bp). The 
first cloning strategy resulted in the 
generation of a fusion protein 
consisting only of srp9 linked to 
srp14 at its 3’ end, omitting 
inclusion of the linker. Therefore, a 
second improved cloning strategy 
was developed, which proved to be 
successful (for exact method of 
cloning see section 5.8.2). The 
resulting gene fragment for the fusion protein was successfully inserted into pDEST17. 
Sequencing analysis confirmed correct pDEST9-myc-14 clones, of which one was selected 
for protein expression in bacteria. 
2.1.5 Expression and purification of SRP9-myc-14 
pDEST17-SRP9-myc-14 was transformed in chemically competent E. coli (RosettaTM) 
and expressed overnight upon IPTG induction (see Methods section 5.6.1 for details). 
After bacterial lysis, His-tagged SRP9-myc-14 was purified using Ni-column affinity 
chromatography. During the purification, aliquots of each step were taken and loaded on 
a polyacrylamide gel to check for enrichment of recombinant protein.  
Figure 12 shows a Coomassie stain with aliquots from SRP9-myc-14 purification. A very 
strong band emerged after induction with IPTG at approximately 27 kDa, fitting to the 
data of the published fusion protein66. The apparent difference to the calculated 
molecular weight (24.5 kDa) was according to Bovia and colleagues due to the very basic 
C-terminal domain of SRP14. Lane 3 shows that the fusion protein was highly expressed 
upon induction, resulting in loss of half protein amount due to the low binding capacity of 
the resin. The fusion protein was eluted in an elution buffer containing 300 mM 
imidazole. 
 
Figure 11: Permutations of SRP9-myc-14 fusion protein. In this 
study, only the permutation depicted on the lower left-hand 
side was generated and expressed. Here, SRP9 was C-
terminally linked to myc, which was linked to the N-terminus 
of SRP14. Modified from Bovia, 1994. 
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Figure 12: Purification of SRP9-myc-14 on Ni-column. 45 µg of cell lysate or protein 
was loaded per sample well. The Coomassie stain shows that upon IPTG induction, 
SRP9-myc-14 was expressed (lane “Uninduced” vs. lane “Induced”). Enrichment of 
SRP9-myc-14 was successful in eluate 1 and 2 (300 mM imidazole), although the 
samples were contaminated with various proteins. Elution 1 and 2 precipitated, there 
fore Wash 4 was used for in vitro processing assays (c = 1.5 µg/µl).  
2.1.6 Analysis of SRP9-myc-14 in processing assay 
For the processing assay, dialysed SRP9-myc-14 was added to radiolabeled pre-miR-138 
and rDcr in several dilutions. Figure 13 shows processing of pre-miR-138 and two control 
precursors, pre-miR-19, and pre-miR-138L1.  
 
 
Figure 13: Dicer in vitro processing assay with SRP9-myc-14 fusion protein. Incubation of varying 
concentrations of the fusion protein with pre-miR-138 and two control precursors resulted in inhibition of all 
three precursors by high concentrations of the fusion protein and relieve of inhibition in dilutions of SRP9-
myc-14. As both controls are processed normally by HeLa cell extracts in contrast to pre-miR-138, this result 
indicated that SRP-9-myc-14 did not possess inhibitory function in Dicer processing. 
 
The single lane represents the positive control with RNAi buffer, showing active Dicer 
processing of the precursor. Comparison of pre-miR-138 with the two controls revealed 
that all three precursors were blocked in processing when adding undiluted or 1:3 diluted 
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fusion protein. Higher dilutions resulted in normal processing activity of Dicer. This 
indicates that the fusion protein binds RNA unspecifically, inhibiting Dicer access to all 
three precursors. 
2.1.7 Analysis of effect of BSA on processing assay 
The processing assay shown in Figure 13 reveals that unspecific binding sites for proteins 
exist on the precursor miRNAs, which might conceal a specific interaction of SRP9/14 
with pre-miR-138. To solve this problem, saturation of these binding sites with bovine 
serum albumin (BSA) was performed. Radiolabeled pre-miR-138 and pre-miR-138L1 
were incubated with rDcr and varying concentrations of BSA. Concentration of undiluted 
BSA solution was 0.8 µg/µl. 2 µl of undiluted or diluted BSA solutions were added to the 
reaction mix. Figure 14 shows that addition of BSA did not block access of Dicer to the 
precursor miRNAs, visualized by unaltered processing activity of Dicer. 
 
 
Figure 14: Dicer in vitro processing assay with BSA. 2 µl of a 0.8 µg/µl BSA 
solution and dilutions thereof were added to radiolabeled substrate and rDcr. 
BSA did not influence Dicer processing in pre-miR-138 or control precursor. 
2.2 RNAi-mediated knockdown of SRP9/14  
2.2.1 Design of siRNAs for SRP9/14 knockdown 
A second strategy to assess whether SRP14 is a potential candidate for inhibition of 
miRNA maturation was to knockdown SRP9 and SRP14 in HeLa using RNA 
interference. For this, siRNAs targeting the genes under investigation were designed using 
two different strategies: first, it should be checked whether knockdown of SRP14 alone 
was sufficient to regain processing activity. Second, a double knockdown of SRP9 and 
SRP14 was performed to assure that both components of the heterodimer were removed. 
For SRP9/14 knockdown, two self-designed siRNAs against SRP14 and one commercial 
  Results 
  25 
siRNA SMARTpool against each SRP9 and SRP14 were ordered at Dharmacon. 
Sequences for self-designed siRNAs were obtained from a program assessing mRNA 
target site accessibility called RNAxs (http://rna.tbi.univie.ac.at/cgi-bin/RNAxs)67 and 
chosen according to the optimal accessibility data. Table 1shows the sequences of siRNAs 
used including a control siRNA against GFP (Proligo).  
siRNA name Target gene Sequence 
siSRP9 SRP9 SMARTpool 
siSRP14 SRP14 SMARTpool 
siSRP14-1 SRP14 GCUGAAGAAGAGAGACAAAUU 
siSRP14-2 SRP14 UCUUUCCCAACCCAUUUUUU 
siGFP - ACUUCAGGGUCAGCUUGCCU 
Table 1: siRNA sequences used in the experiments. Dh1, Dh2: 
Dharmacon smartpools 1, 2. siGFP served as a control, targeting no 
gene in HeLa cells. 
2.2.2 SRP9/14 Knockdown in HeLa cells 
To reduce the expression of SRP9 and SRP14 in HeLa cells, 4 different siRNAs were 
transfected into HeLa cells for 3 days, or 7 days in case a re-transfection was performed. 
Knockdown efficacy of the siRNAs was tested using Western Blot analysis. For this, 20 µg 
protein extracts of HeLa cells transfected with different siRNAs were loaded on a 
polyacrylamide gel. After blotting, the membrane was probed with antisera against 
SRP14. Figure 15 shows a robust reduction in SRP14 protein levels upon transfection of 
siSRP9, siSRP14, both, and siSRP14-1. Transfection of siSRP-14-Dh2 yielded a less 
strong reduction of SRP14. Interestingly, knockdown of SRP9 resulted in a decrease of 
SRP14 protein levels, possibly because SRP14 exists in complex with SRP9 and is 
degraded faster as a monomer. It has been observed that SRP14 was rather sensitive to 
proteolytic degradation (Bovia 1995). A siRNA against GFP not targeting any gene in 
HeLa cells was used as a control. Higher knockdown efficacy was achieved in cell extracts 
harvested three days after transfection than in those harvested after 7 days and a second 
transfection. This could have resulted from a higher replication rate of untransfected, 
unstressed cells, which might have overgrown SRP9/14 depleted cells. The experiments 
indicate that siSRP9, siSRP14, both, and siSRP14-1 cause knockdown of endogenously 
expressed SRP14 protein levels in transfected HeLa cells. 
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2.2.3 Analysis of processing activity in depleted HeLa cells 
To examine whether SRP9/14-depleted HeLa cell extracts were able to recover Dicer 
activity and therefore produce the mature miR-138, in vitro processing assays using 
recombinant Dicer enzyme (rDcr) and radiolabeled pre-miR-138 were performed. If 
SRP14 were the candidate, one would expect to detect cleavage by Dicer in the SRP14-
depleted cell extracts or at least stronger bands than in control cells. The result given in 
Figure 15 indicates that knockdown of SRP9, SRP14 or both did not influence the 
inhibition of processing in HeLa cell extracts as the resulting band pattern revealed no 
difference between SRP14-depleted and control cells (siGFP, siSRP14-Dh2). As a positive 
control for Dicer activity, labeled substrate was incubated with rDcr and RNAi buffer. 
Based on this and previous results of the recombinant protein, SRP14 was excluded from 
the list of putative Dicer inhibitors.  
 
Figure 15: (A) Evaluation of siRNAs targeting SRP9 and SRP14. 20 pmol of different siRNAs 
including control siGFP were transfected into 70% confluent HeLa cells. Cells were harvested 3 or 
7 days after transfection. SRP14 expression levels were monitored by Western Blot using 
commercial antisera against SRP14 (1:1000). For loading control, the blot was probed with antisera 
against !-tubulin. (B) Radiolabeled pre-miR-138 was incubated with rDcr and depleted HeLa 
extracts as indicated on top. Undiluted extracts or 1:2 and 1:10 dilutions were used. Buffer alone 
served as positive control (first lane). No difference of processing activity between control extracts 
(siGFP, siSRP14-Dh2) and SRP14-depleted extracts were observed. 
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3. Discussion 
miR-138 is a brain-specific miRNA. In kidney, liver and lung tissues as well as HeLa cells 
the precursor of miR-138 accumulates and is never processed to the mature and 
functional miRNA60. This maturation step fails to take place due to the intervention of a 
proteinaceous inhibitory factor58. The aim of this thesis was to test one protein candidate 
for its putative role in inhibition of miR-138 maturation in HeLa cells. A search for 
candidate proteins by comparing mass-spectrometry results from two different 
purification strategies yielded a single promising candidate: signal recognition particle 14 
(SRP14). SRP14 forms a complex with SRP9 and exerts its only known function as part of 
the multi-domain protein complex SRP, co-translationally sorting proteins to the 
endoplasmic reticulum. Interestingly, in primate cells, SRP9/14 exists also in a free 
cytoplasmic form, bound to Alu-like RNAs. While murine SRP9/14 does not exist in 
excess over SRP, primate SRP9/14 was found to be in more than 20-fold excess in HeLa 
cells and three other primate cell lines. Furthermore, human SRP14 contains a C-
terminal repeat domain not present in murine SRP14. Thus, an additional function for 
this heterodimer has been assumed (Bovia 1995). The fact that murine and primate 
SRP14 differ in several aspects challenged the hypothesis that SRP9/14 was involved in 
the miRNA pathway. Obernosterer et al. detected accumulation of precursor and lack of 
mature product both in mouse tissues and HeLa cell extracts60. Nevertheless, the 
congruence in mass-spectrometry data and the RNA-binding ability of the candidate 
protein prompted us to examine the role of SRP14 in inhibition of pre-miR-138 
processing by addition of the recombinant SRP14 to the Dicer in vitro processing assay, 
and by RNAi-mediated knockdown and subsequently testing cellular extracts for 
inhibitory activity. 
In the last years, much work has been done to elaborate the exact binding conditions and 
three-dimensional structure of SRP domains68, 69. One very promising hint that SRP14 
might be the inhibitor lies in the structure of the RNA binding protein and its known 
interactor 7 SL RNA in SRP.  
Both SRP9 and SRP14 bind to the 5’ end 3’ ends of 7SL RNA in mammalian SRP, 
forming the Alu domain (Figure 16). The SRP9/14 heterodimer clamps together the open 
ends of the RNA by folding into a six-stranded !-sheet with a positively charged concave 
surface, which binds the negatively charged Alu domain RNA. SRP9/14 also interacts 
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with rRNA of the ribosome68, 69. The secondary structure of the Alu RNA contains a 
three-way junction of stems known as "-junction in three-dimensional arrangement. A 
central U-turn in this substructure is specifically recognized by SRP9/14 and 
characterized by the conserved sequence UGUURR, where the second U forms the U-
turn and R stands for a conserved purine69. Examination of the sequence of pre-miR-138 
revealed that the consensus sequence required for binding of SRP9/14 is nearly 
completely present on the 5’ arm of pre-miR-138 (Figure 6): UGUUGU.  
SRP9/14 represented an 
attractive candidate for the 
inhibitor based on the arguments 
mentioned above. As SRP plays a 
crucial role in the maintenance of 
cellular function, all SRP 
subunits including SRP9/14 are 
expressed in every cell type 
comprising neural cells. 
Therefore, an explanation for the 
lack of inhibitory function of 
SRP9/14 in neural tissues is 
indispensable.  
One possibility why the 
ubiquitously expressed protein 
SRP9/14 does not act as an 
inhibitor in neural cells could be 
the existence of an RNA 
transcript in brain, which serves 
as an energetically more 
favorable RNA binding substrate for SRP9/14 than pre-miR-138. This RNA transcript 
could titrate out the inhibitor and release a free pre-miR-138, enabling precursor 
maturation. A second explanation could be that SRP9/14 is expressed in 20-fold excess 
only in tissues others than brain and that the expression level in neural cells is not 
sufficient for heterodimer formation independent of SRP.  
 
 
Figure 16: (Top) Secondary structure of human SRP RNA with the 
heterodimer SRP9/14 bound. Adapted from Birse 1997. (Bottom) 
Three-dimensional representation of Alu domain crystal structure 
containing SRP9 (red) and SRP14 (green) bound to RNA. Adapted 
from Nagai 2003. 
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To test the candidate protein, recombinant SRP9/14 was generated and added to the 
Dicer processing assay. Processing of pre-miR-138 was indeed inhibited upon addition of 
recombinant SRP9/14 fusion protein. However, processing of control precursors was 
inhibited as well, indicating that unspecific binding of SRP9/14 to RNA sequences 
blocked the access of Dicer to all tested precursors similarly (Figure 13). Inhibition was 
only achieved with high concentrations of recombinant protein. Addition of BSA to the 
assay was performed to test for concentration-dependent unspecific RNA binding. No 
difference in processing activity was observed with increasing BSA concentrations in both 
control precursor and pre-miR-138 (Figure 14).  
Expressing functional recombinant proteins is often prone to failure. In principle, 
expression can be performed in prokaryotic or eukaryotic systems. Prokaryotic systems 
like the E. coli system used in this study provide several advantages: ease of culture, fast 
growth, easy induction (e.g. IPTG), simple and numerous purification options. On the 
other hand, recombinant expression of proteins particularly from eukaryotic genes may 
result in partial or complete loss of enzymatic activity due to the lack of post-translational 
modifications or misfolding of the protein as the bacterial cellular interior does not 
provide the folding environment possibly required. Eukaryotic systems (yeast, mammalian 
cells, insect cells) are advantageous in many ways but more difficult to handle. In this 
study, SRP9, SRP14 and the fusion protein were expressed in bacterial systems. As the 
proteins do not possess an enzymatic function and proved to be soluble, it was decided to 
stay with the bacterial system.  
A weak point of the experimental setup is the fact that the SRP RNA binding 
characteristics of the recombinant proteins were never checked after purification from the 
lysate as has been done in previous studies66. Consequently, due to the denaturing 
conditions of the purification and elution with high concentrations of imidazole, it is 
possible that proper refolding of the fusion protein was not accomplished, resulting in 
impaired SRP9/14 function.  
Furthermore, an antibody against SRP14 was available at time of the experiments, but 
successful enrichment of SRP14 or the fusion protein was concluded only from the 
detection of a strong band of expected size emerging after IPTG induction (Figure 9, 
Figure 12). To confirm the expression of SRP14 or the fusion protein, a Western Blot 
probing for SRP14 should have been performed.  
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BSA is used in numerous biochemical applications to reduce unspecific binding of 
proteins to surfaces (Western blot, immunostainings) or to stabilize enzymes during 
restriction digests, but is less well known for RNA binding activity. To examine whether a 
candidate protein has a specific function on miRNA processing, other groups have used 
hnRNP A1, YBX-2, Msi-2 or hnRNPL as control RNA binding proteins54. Nevertheless, 
in this study BSA added to the in vitro Dicer processing assay to block unspecific protein 
binding sites on control precursors.  
The results of the assay involving recombinant candidate protein were not clear enough to 
allow exclusion of SRP9/14 from the list of putative inhibitors. Therefore, a second 
approach was pursued to check for inhibitory activity of SRP9/14.  
For this, RNAi-mediated knockdown of SRP9/14 was performed. Depleted HeLa cell 
extracts were then added to the Dicer in vitro processing assay. However, removal of 
SRP14 from cellular extracts did not yield mature miR-138, implying that SRP14 is not 
involved in inhibition of Dicer processing and that the sought-after inhibitor was still 
present in the SRP14-depleted extracts.  
3.1 Perspectives 
Once the inhibitor of miRNA maturation has been identified, several experiments could 
be devised for validation as well as further investigation of the regulatory mechanism. 
Validation experiments include in vitro studies with recombinant protein and inhibitor-
depleted HeLa cell extracts as described in this thesis. Furthermore, an 
immunoprecipitate of the inhibitor from HeLa cells could be added to the in vitro 
processing assay and checked for its effect on miRNA maturation. Inhibitor-depleted 
HeLa cell extract could be complemented with recombinant inhibitor and should regain 
the inhibitory effect. 
The role of the inhibitor on processing should be investigated not only in vitro but also in 
vivo. One possibility is to ectopically express the protein factor and pre-miR-138 in cell 
lines normally processing pre-miR-138 and checking for impaired maturation by 
Northern Blotting. Ectopical expression of only the protein factor followed by 
measurement of endogenous miRNA levels by quantitative PCR would provide further 
evidence for in vivo relevance of the protein factor.  
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To confirm a direct interaction of the inhibitor with pre-miR-138, one could perform a 
co-sedimentation assay or an electromobility shift assay (EMSA) using radiolabelled pre-
miR-138. However, to gain structural insights into the regulatory mechanism, fragments 
of pre-miR-138 would have to be generated and tested for inhibitor binding sites by 
EMSA. In addition, sequence analysis by single-nucleotide mutations could reveal 
conserved nucleotides crucial for inhibitor binding. The role of loop 1 in pre-miR-138 
maturation has to be investigated further.  
Next, to assess the influence of inhibitory activity on miRNA target regulation, one could 
construct a Luciferase-based reporter assay where target sites for miR-138 are cloned 
downstream of the luciferase gene into a vector. Overexpression of miR-138 in HeLa cells 
transfected with this vector should lead to a decrease of luciferase activity as miR-138 
binds to its target sites on the vector and down-regulates luciferase gene expression. In 
contrast, RNAi-mediated knockdown of the inhibitor in HeLa cells would result in 
enhancement of luciferase gene expression as the inhibitor blocks generation of a mature 
and functional miR-138.  
Finally, domain analysis of the inhibitor could provide information on RNA-binding or 
catalytic domains. Single amino acid substitutions in the protein factor could reveal amino 
acid residues required for proper function of the inhibitor.  
However, it is not known whether the inhibitor of pre-miR-138 is a factor solely destined 
for miR-138 regulation or plays a role in the biogenesis of dozens of miRNAs. 
Investigation of the specificity of the inhibitor poses another interesting research topic. 
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4. Materials 
All standard chemicals for preparing buffers and solutions were purchased from Fluka, 
Sigma Aldrich, or AppliChem. Specific chemicals, kits and consumables were purchased 
as listed below. Solutions and buffers were prepared as described below. 
4.1 Kits and Consumables 
Item Supplier Order No. 
Amersham Hybond™ - N+ GE Healthcare RPN303B 
Amersham Hyperfilm™ ECL 18x24 cm GE Healthcare 28906937 
AmpliScribe™ T7-Flash™ Transcription Kit  Biozym Scientific 150.407 
BioRad Protein Assay BioRad Laboratories GmbH 500-0006 
ECL™ Western Blot Detection Kit GE Healthcare RPN2106V1/V2 
Kodak Biomax XAR film Sigma Aldrich F5513-50EA 
Lipofectamine® 2000 Reagent Invitrogen 11668-019 
MF™ Membrane Filtern 0.025 µm Millipore VSWP02500 
PhastGel Blue R Pharmacia Biotech 17-0518-01 
Plasmid Maxi Kit Qiagen 12163 
Plasmid Mini Kit Qiagen 27106 
QiaEx II Agarose Gel Extraction Kit Qiagen 28704 
4.2 Chemicals 
4.2.1 Protein applications 
Reagent Supplier Order No. 
1,4-Dithiothreitol (DTT) Roche Diagnostics 10708984001 
Ammonium persulfate (APS) National Diagnostics EC-504 
complete, EDTA-free Roche Diagnostics 11873580001 
Ni-NTA Agarose Qiagen 1018244 
Precision Plus Protein™ Dual Color Standards BioRad Laboratories 161-0374 
ProtoGel National Diagnostics EC-890 
Purified BSA 10 mg/ml 100x New England Biolabs B9001S 
N, N, N', N'-tetramethylethylenediamine (TEMED( National Diagnostics EC-503 
Tween® 20 Fluka 93779 250 g 
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4.2.2 Nucleic acid applications 
Reagent Supplier Order No. 
Ammonium persulfate (APS) National Diagnostics EC-504 
Bromophenol blue Merck 1.08122.0005 
Chloroform-Isoamyl alcohol AppliChem A1935,0250 
Ethidium Bromide Fluka 46065 
Gener Ruler 1 kb Fermentas SM0313 
GeneRuler 100 bp Fermentas SM0243 
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
(HEPES) 
AppliChem A3268,0250 
Phenol-Chloroform-Isoamyl alcohol pH 4 AppliChem A2279,0250 
Phenol-Chloroform-Isoamyl alcohol pH 8 AppliChem A0889,0500 
SeaKem® LE Agarose Lonza 50004L 
Sequagel Buffer National Diagnostics EC-835 
Sequagel concentrate National Diagnostics EC-830 
Sequagel Diluent National Diagnostics EC-840 
SIGMACOTE® (silane) Sigma-Aldrich SL2-100ml 
N, N, N', N'-tetramethylethylenediamine (TEMED) National Diagnostics EC-503 
4.3 Antibodies 
Reagent Host Supplier Order No. 
#-!-tubulin Mouse Sigma-Aldrich T4026 
Goat anti-mouse IgG (H+L) - HRP Goat Invitrogen 62-6520 
Goat anti-rabbit IgG (H+L) - HRP Goat Invitrogen 62-6120 
#-SRP14 Rabbit Proteintech Group 11528-1-AP 
4.4 Enzymes 
Reagent Concentration Supplier 
Alkaline Phosphatase 20 U/µl Roche Diagnostics 
BamHI 20,000 U/µl New England Biolabs 
Gateway® BP Clonase® II enzyme mix - Invitrogen 
Gateway® LR Clonase® II enzyme mix - Invitrogen 
EcoRI 20,000 U/µl New England Biolabs 
GIBCO™ 0.5% Trypsin-EDTA 10x - Invitrogen 
HpaI 5,000 U/µl New England Biolabs 
Phusion™ Polymerase 2 U/µl New England Biolabs 
Proteinase K - Sigma-Aldrich 
Recombinant Dicer 1 U/µl Ambion 
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T4 DNA Ligase 400,000 U/µl New England Biolabs 
T4 Polynucleotide Kinase 10,000 U/µl New England Biolabs 
Taq Polymerase 5U/µl Eppendorf 
Taq Polymerase 5U/µl 5 PRIME 
4.5 Plasmids 
Plasmid Supplier Order No. 
pDONR201 Invitrogen 11798014 
Gateway pDEST 17 Vector Invitrogen 11803012 
4.6 Oligonucleotides and radionucleotides 
4.6.1 General Oligonucleotides 
attB AAAAAGCAGGCTNN 
attB2 AGAAAGCTGGGTN 
SRP914-LNK-AS 
GATCGCCCCGGCTGTCGTCCTCCTCGCTGATCAGCTTCTGCT 
CGCCGCCC 
SRP914-LNK-SE 
AATTGGGCGGCGAGCAGAAGCTGATCAGCGAGGAGGACGAC 
AGCCGGGGC 
T7 promoter TTAATACGACTCACTATAGG 
4.6.2 Cloning Oligonucleotides (Primers) 
attB1-fwd GGGGACAAGTTTGTACAAAAAAGCAGGCT 
attB2-rev GGGGACCACTTTGTACAAGAAAGCTGGGT 
SRP9-fwd AAAAAGCAGGCTCAATGCCTCAGTTCCAGACCTGGG 
SRP9-rev AGAAAGCTGGGTCTCATTCTGTTTCCATAGTGACATTGCGG 
SRP9-rev-EcoRI CCGGAATTCTGTTTCCATAGTGACATTGCGG 
SRP14-fwd AAAAAGCAGGCTCAATGGTGTTGCTCGAGAGCGAGC 
SRP14-fwd-BamHI CGCGGATCCCATGGTGTTGCTCGAGAGCGAGC 
SRP14-rev AGAAAGCTGGGTCTCACTGTGCTGGTTTGCTCTTCTTAC 
4.6.3 Sequencing Oligonucleotides 
SRP9-fwd AAAAAGCAGGCTCAATGCCTCAGTTCCAGACCTGGG 
SRP9-rev AGAAAGCTGGGTCTCATTCTGTTTCCATAGTGACATTGCGG 
SRP9-rev-EcoRI CCGGAATTCTGTTTCCATAGTGACATTGCGG 
SRP14-fwd AAAAAGCAGGCTCAATGGTGTTGCTCGAGAGCGAGC 
SRP14-fwd-BamHI CGCGGATCCCATGGTGTTGCTCGAGAGCGAGC 
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SRP14-rev AGAAAGCTGGGTCTCACTGTGCTGGTTTGCTCTTCTTAC 
4.6.4 miRNA precursor sequences 
pre-miR-19 
AGUUUGCAUAGUUGCACUACAAGAAGAAUGUAGUUGUGCAAAUCUA 
UGCAAAACUGA 
pre-miR-138 
AGCUGGUGUUGUGAAUCAGGCCGACGAGCAGCGCAUCCUCUUACCC 
GGCUAUUUCACGACACCAGGGUU 
pre-miR-138L1 
AGCUGGUGUUGUGAAUCAGGCCGACGAGCAGCGCAUCCUCUUACCC 
GGCUUGAUUCACGACACCAGGGUU 
4.6.5 Radionucleotides 
Reagent Concentration Supplier 
[$-32P] dATP 3000 Ci/mmol, 10mCi/ml Perkin-Elmer (Easytides) 
4.7 Buffers and Solutions 
4.7.1 Protein applications 
1 M DTT 7.71 g in 50 ml dH2O 
1 M IPTG 2.38 g in 10 ml dH2O 
10% APS 1 g APS in 10 ml dH2O 
10x PBS 80 g NaCl, 2 g KCl, 11.6 g Na2HPO4.7H2O, 2 g KH2PO4,  
Dissolve in 1000 ml dH2O, pH 7.3 (HCl) 
10x SDS-PAGE Running Buffer 250 mM Tris Base, 1.92 M Glycine, 1% w/v SDS 
10x Semidry-Blot Buffer 57.6 g Glycin, 12 g Tris, 4 ml 20% SDS, add H2O to 400 ml;  
10x Buffer:MeOH:H2O = 1:1:8 
1x PBS-T 1 ml Tween® 20 in 1000 ml 1x PBS 
2x Cracking buffer 125 mM Tris pH 6.8, 25% v/v Glycerol, 5% w/v SDS,  
0.01% w/v bromophenol blue, 1:10 1 M DTT (fresh):  
5 ml 1M Tris, 11.5 ml 87% Glycerol, 20 ml 10% SDS 1 tip B-blue,  
ad 40 ml dH2O 
5x Sample buffer 62,5 mM Tris pH 6.8, 25 mM EDTA pH 8.0, 5% w/v SDS,  
5% v/v b-mercaptoethanol, 0.025% w/v  bromophenol blue,  
50% v/V glycerol 
Blocking solution 4 g non-fat dry milk in 100 ml PBST 
Coomassie staining solution 8 ml 20% Acetic Acid, 8 ml PhastGel Blue R (1 tablet in  
4:6dH2O:MeOH) 
Coomassing destaining solution 60 ml dH2O, 10 ml acetic acid, 30 ml methanol 
HeLa Lysis Buffer 
50 mM HEPES pH 7.4, 1% NP-40, 100 mM KCl, 5 mM MgCl2,  
10% Glycerol, 0.1 mM AEBSF, 0.5 mM DTT (fresh); 10 ml 1M HEPES, 2 ml NP-40, 7 ml 3 M KCl, 1 ml 1 M MgCl2, 3 ml 87% Glycerol, 0.5 ml 40 mM AEBSF, 1:2000 of 1 M DTT, 176.5 ml dH2O 
Washbuffer His-tag 100 mM NaCl, 50 mM Tris-Cl pH 8, 5 mM !-Mercaptoethanol,  
0.1 mM AEBSF Protease Inhibitor, ad 1000 ml dH2O 
Washbuffer His-tag 25 mM imidazole 100 mM NaCl, 50 mM Tris-Cl pH 8, 5 mM !-Mercaptoethanol,  
0.1 mM AEBSF Protease Inhibitor, 25 mM imidazole, ad 1000 ml dH2O 
Washbuffer His-tag 50 mM imidazole 100 mM NaCl, 50 mM Tris-Cl pH 8, 5 mM !-Mercaptoethanol,  
0.1 mM AEBSF Protease Inhibitor, 50 mM imidazole, ad 1000 ml dH2O 
Washbuffer His-tag 100 mM imidazole 100 mM NaCl, 50 mM Tris-Cl pH 8, 5 mM !-Mercaptoethanol,  
0.1 mM AEBSF Protease Inhibitor, 100 mM imidazole, ad 1000 ml dH2O 
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Washbuffer His-tag 300 mM imidazole 100 mM NaCl, 50 mM Tris-Cl pH 8, 5 mM !-Mercaptoethanol,  
0.1 mM AEBSF Protease Inhibitor, 300 mM imidazole, ad 1000 ml dH2O 
4.7.2 RNA and DNA applications 
1 M HEPES Dissolve 24 g in 100 ml water, adjust pH with 5 M KOH to pH 7.4 
100 mM ATP 4,236 g in 14 ml dH2O (500 mM), dilute to 100 mM 
10x TBE 108 g Tris, 9.3 g EDTA, 55 g Boric acid, ad 1 L dH2O 
2x Formamide 1 ml 0,5 M EDTA, 9 ml formamide, 10 ng bromophenol blue,  
10 ng xylene cyanol 
2x STOP Buffer 24 g urea, 4 ml 0.5 M EDTA, 10 ng bromophenol blue, dH2O ad 50 ml 
Dicer reaction buffer 30 mM Tris, 50 mM NaCl, 3 mM MgCl2, 1 mM DTT, 10% glycerol 
Orange G Loading Buffer 0.5% Orange G in 50% glycerol 
RNAi buffer (100 mM KCl) 30 mM HEPES, 100 mM KCl, 5 mM MgCl2, 10% glycerol; 30 ml  
1 M HEPES, 5 ml 1 M MgCl2, 33 ml 3 M KCl, 113 ml 87% Glycerol,  
819 ml dH2O 
TE Buffer 10 ml 1M Tris, 2 ml 0.5 M EDTA, ad 1 L dH2O 
TN Buffer 10 mM Tris pH 8.0, 100 mM NaCl 
 
4.8 Cells 
4.8.1 Mammalian cells 
Cell line Supplier Order No. 
HeLa IMBA collection - 
4.8.2 Bacteria 
Strain Supplier Order No. 
E. coli DH5# IMBA collection - 
E. coli Rosetta™ IMBA collection (Novagen) - 
4.9 Media 
4.9.1 Basic cell culture medium 
Reagent Supplier Order No.  
GIBCO™ DMEM 1x Invitrogen 10938-025 500 ml  
GIBCO™ Opti-MEM I 1x Invitrogen 31985-047 500 ml  
Penicillin-Streptomycin Solution Sigma-Aldrich P0781  
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L-Glutamine 200 mM Sigma-Aldrich G7513  
    
DMEM for HeLa cells 
 
Add 50 ml FCS, 5 ml Penicillin-Streptomycin, 7.5 ml  
Glutamine, 10 ml 1 M HEPES pH 7.4 to 500 ml DMEM 
4.9.2 Special cell culture medium 
Freezing Medium 90% DMEM with 15% FCS, 10% DMSO 
4.9.3 Bacterial medium 
   
LB 10 g Bacto Tryptone, 5 g Yeast Extract, 5 g NaCl, ad 1 L dH2O, pH 7.47 
(NaOH) 
2x TY-MED 16 g Tryptone, 10 g Yeast Extract, 5 g NaCol, ad 1 L dH2O, pH 7.4 (NaOH) 
4.9.4 Antibiotics 
Antibiotic Supplier Order No. 
Ampicillin sodium salt AppliChem A0839,0010 
Kanamycin sulfate AppliChem A1493,0025 
4.10 Appliances 
Appliance Supplier 
Adjustable nucleic acid sequencing unit C.B.S. Scientific 
AlphaImager Biozym Scientific 
Analytical Balance CP64 Sartorius 
Biofuge Pico Benchtop Centrifuge Heraeus 
DNA Engine Peltier Thermal Cycler Bio-Rad Laboratories 
Dual adjustable nucleic acid sequencer C.B.S. Scientific 
Image Eraser Amersham Biosciences 
Isotemp 210 Fisher Scientific 
Model 583 Gel Dryer Bio-Rad Laboratories 
Multifuge 3 Heraeus 
Multitron II Incubator Shaker Infors 
NanoDrop 1000 Thermo Fisher Scientific 
pH Meter Level 1 inoLab 
PicoFuge Microcentrifuge Stratagene 
Power Pac™ 3000 / HV Bio-Rad Laboratories 
PTC-200 Peltier Thermal Cycler MJ Research 
RC 5C Plus Superspeed Centrifuge Sorvall 
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Rocketing Platform Biometra 
Rotator SB3 Stuart® 
SmartSpec Plus Spectrophotometer Bio-Rad Laboratories 
Thermomixer® Comfort Eppendorf 
Top Loading Balance CP2201 Sartorius 
Trans-Blot® SD Semi-dry Transfer Cell Bio-Rad Laboratories 
Typhoon  TRIO Amersham Biosciences 
4.11 Software 
4Peaks http://mekentosj.com/4peaks/ 
AlphaImager Alpha Innotech 
Excel Microsoft 
Illustrator 10 Adobe 
Multalin http://bioinfo.genotoul.fr/multalin/multalin.html 
Photoshop 7.0 Adobe 
PlasmaDNA http://research.med.helsinki.fi/plasmadna/ 
Reverse Complement http://www.bioinformatics.org/SMS/rev_comp.html 
RNAxs http://rna.tbi.univie.ac.at/cgi-bin/RNAxs 
Tm Calculator http://www.appliedbiosystems.com/support/techtools/calc/ 
Word Microsoft 
XPlasMap http://www.panix.com/~iayork/XPlasMap/ 
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5. Methods 
Relevant chemicals, buffers, and solutions are listed in section 4 (“Materials”). 
5.1 Mammalian Cell Culture 
5.1.1 Standard cell culture 
Standard condition for incubation of HeLa cells was 37°C in a humidified incubator 
supplemented with 5% CO2.  
5.1.2 Splitting of cells 
Fresh plates with warm DMEM were prepared. Old medium was removed and cells were 
washed once with 1x PBS. After removing PBS, an appropriate volume of 1x Trypsin-
EDTA was added (see Table 2) and the plate tilted to spread trypsin over the cells. 
Incubation of the cells for 2-5 minutes at 37°C resulted in the loss of cell adherence to the 
plate and the reaction was stopped by adding warm DMEM starting from the bottom of 
the plate to avoid the formation of cell clumps. Rotation of the plate should be avoided 
due to accumulation of cells at the plate walls. Cells were incubated at 37°C over night. 
HeLa cells growing on a 10 cm dish were split twice a week 1:10.  
 
 Surface area Plating medium PBS wash Trypsin DMEM1) 1:102) 1:53) 
10 
cm 
plate 
60 cm2 10 ml 10 ml 0,5 ml 5 ml 0,5 ml 1 ml 
6-
well 
plate 
10 cm2 2 ml 2 ml 0,1 ml 1 ml 0,1 ml 0,2 ml 
Table 2: Overview of volumes needed for splitting cells. 
 
1) Volume of medium to stop reaction 
2) Volume of cells transferred to the new plate / well for 1:10 split 
3) Volume of cells transferred to the new plate / well for 1:5 split 
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5.1.3 Freezing of cells 
A confluent 10 cm dish was trypsinized and washed once with 1x PBS. The cells were 
resuspended in freezing medium to 2x 106 cells/0.5 ml medium and stored in 1 ml cryo-
vials at -80°C using a freezing box filled with isopropanol. After 24 hours, the cryo-vials 
were placed into a liquid-nitrogen container for long-term storage.  
5.1.4 Thawing of cells 
Aliquots containing HeLa cells were stored at -186°C in liquid nitrogen. The tube was 
thawed in a water bath heated to 37°C until only a little block of ice was left and then 
immediately put on ice. 10 ml warm DMEM were added dropwise. The cells were 
spinned down (2’, 200 x g, RT). The supernatant was removed and after resuspending the 
cell pellet in 10 ml warm DMEM the cells were seeded on a 10 cm dish.  
5.1.5 Transfection of adherent cells with siRNAs 
Cells were seeded on a 6-well plate at a density of ~ 2x 105 cells per well in 2 ml DMEM 
and incubated until the cells were 70-80% confluent (18-24 hours). For the transfection, 
two solutions per siRNA were separately prepared. In solution 1, 250 µl Opti-MEM were 
mixed with 100 pmol siRNA and the tube vortexed. In solution 2, 250 µl Opti-MEM 
were mixed with 5 µl Lipofectamine™ 2000, the tube was vortexed and incubated for 5 
minutes (RT). Preparation of a master mix (x times 250 µl Opti-MEM + x times 5 µl 
Lipofectamine™ 2000) is recommended. Both solutions were vortexed and incubated for 
5 minutes at room temperature. Then the two solutions were combined, mixed carefully 
and incubated for 20 minutes at room temperature. In the meantime, cells were washed 
once with 1x PBS and incubated in 2 ml Opti-MEM per well until transfection time. For 
the transfection, the siRNA-containing transfection reagent was added to the wells 
dropwise and the cells were incubated for 6 hours. Then Opti-MEM was removed and 2 
ml DMEM were added per well. After three days 75% of the cells per well were harvested 
for generating whole cell extracts, while the remaining 25% of the cells were seeded on a 
new 6 well-plate and transfected a second time in the same way like before. Three days 
later the cells were harvested for whole cell extracts.  
To knockdown SRP9/14 in HeLa cells, the following volumes were used for transfection: 
Solution 1: 6 x 250 µl Opti-MEM + 6 x 5 µl LipofectamineTM 
Solution 2: 6 different solutions according to Table 3. 
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Opti-MEM siRNA Stock Final Amount RNA Volume pipetted 
250 µl siGFP 10 mM 100 pmol 10 µl 
250 µl siSRP9 20 mM 100 pmol 5 µl 
250 µl siSRP14 20 mM 100 pmol 5 µl 
250 µl siSRP9/14 20 mM/20 mM 100 pmol 2.5µl/2.5µl 
250 µl  siSRP14-1 10 mM 100 pmol 10 µl 
250 µl siSRP14-Dh2 10 mM 100 pmol 10 µl 
Table 3: Transfection scheme and reagent concentration for SRP9/14 knockdown. 
 
The volume of reagents needed depends on the surface area of the cell culture plate. An 
overview of the used volumes based on the manufacturer’s instructions and experience 
with transfection in the laboratory is given in Table 4. 
 
Shared reagents DNA transfection RNA transfection Culture 
vessel 
Surf. 
area 
per 
well 
Vol. of 
plating 
medium 
Vol. of 
dilution 
medium 
DNA Lipofect-
amine™ 
2000 
RNA Lipofect-
amine™ 
2000 
96-well 0.3 cm2 100 µl 2 x 25 µl 0.2 µg 0.5 µl 5 pmol 0.25 µl 
24-well 2 cm2 500 µl 2 x 50 µl 0.8 µg 2 µl 20 pmol 1 µl 
12-well 4 cm2 1 µl 2 x 100 µl 1.6 µg 4 µl 40 pmol 2 µl 
6-well 10 cm2 2 µl 2 x 250 µl 4 µg 10 µl 100 pmol 5 µl 
60-mm 20 cm2 5 µl 2 x 500 µl 8 µg 20 µl 200 pmol 10 µl 
10-cm 60 cm2 10 µl 2 x 1.5 ml 24 µg 60 µl 600 pmol 30 µl 
Table 4: Transfection scheme and reagent concentration for different plates. 
 
5.1.6 Lysis of adherent cells 
Freshly harvested cells or frozen pellets were resuspended in an appropriate volume of 
HeLa Lysis Buffer (e.g. 6 x 50 µl for 6-well plate). The cell suspension was pipetted up and 
down a few times to induce rupture of the cell membranes, followed by centrifugation of 
the lysate (15’, 16 000 x g, RT). The supernatant was used immediately or snap-frozen 
and stored at -20°C as whole cell extract.  
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5.2 Bacterial culture techniques 
5.2.1 Standard cell culture 
For all experiments, Escherichia coli bacteria from the strain DH5# or BL21 (Rosetta™, 
Novagen) were used. Bacteria were generally cultured 12-16 hours either as suspension in 
LB medium using a shaking incubator (220 rpm, 37°C) or on agar-containing LB plates 
(37°C incubator). For fast growing needs, bacteria were incubated in 2x TY-MED for 8-
10 hours. When required, antibiotics were added to the media in the following 
concentrations: 
 
Antibiotic Concentration Stock Dilution Final Concentration 
Ampicillin 100 mg/ml 1:1000 100 µg/ml 
Kanamycin 30 mg/ml 1:1000 30 µg/ml 
 
5.2.2 Generation of chemically competent E. coli 
Chemically competent E. coli were prepared and provided by Ivan Botto from the IMBA 
service department. 
5.2.3 Transformation of plasmids into E. coli 
For the standard transformation protocol, 100 µl of competent E. coli stored at -80°C were 
thawed on ice and mixed with varying volumes of the ligation mix or 50 ng of plasmid 
DNA (standard amount). After incubation on ice for 30 minutes, the cells were subjected 
to a heat shock at 42°C for two minutes and cooled down on ice for 3 minutes. For 
regeneration, they were then incubated in 1 ml pre-warmed LB medium without 
resistances for at least 60 minutes in a shaker (750 rpm, 37°C). After centrifugation (2’, 
3400 x g, RT) using a tabletop centrifuge 900 µl supernatant were removed, the pellet was 
resuspended in the remaining medium and plated out on a LB plate with the 
corresponding resistance (LBAmp or LBKan). The plate was incubated over night at 37°C.  
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5.3 DNA techniques 
5.3.1 General DNA protocols 
Standard DNA methods (restriction digestion, cloning methods) were performed 
according to the manufacturer’s instructions. Modifications are indicated where 
necessary. Plasmid preparation was performed using the QIAprep Spin Miniprep Kit 
(Qiagen). For standard plasmid isolation (miniprep), 5 ml LB or 2x TY-MED with the 
appropriate selective antibiotics were inoculated with a single colony from a LB plate. 
The purification protocol was performed according to the instructions given in the 
manual. To elute the plasmid DNA, 30 µl elution buffer or dH2O were added to the 
center of the column and DNA concentration was determined by photometrical 
measurement at 260/280 nm (1:50 dilution in dH2O). 
5.3.2 Agarose gel electrophoresis 
To separate DNA on agarose gels, agarose was mixed with 0.5x TBE to the desired 
concentration (e.g. 1.5 g agarose in 100 ml TBE for a 1.5% gel) and heated in a 
microwave until the powder was completely dissolved. After cooling down of the solution 
using running tap water, ethidium bromide was added in a 1:10 000 dilution. The gel was 
poured into a casting tray for polymerization at RT. DNA samples were pipetted into 
sample wells after mixing with 5x Orange G loading buffer. An appropriate DNA marker 
was loaded beside the samples (2-5 µl). A typical 100 ml gel was run in 0.5x TBE at 100 V 
for one hour. DNA fragments were visualized by exposing the gel to UV-light. 
5.3.3 Conventional Polymerase Chain Reaction 
PCRs were usually run with three different concentrations of template DNA: undiluted 
sample, 1:10 and 1:100. The concentration of the primer stock solution was always 10 
µM. Dilutions of template or primer were made with dH2O. The PCR reaction was 
carried out in a volume of 50 µl using a thermal cycler. Two different protocols described 
in the following were performed. 
5.3.3.1 PCR using Taq DNA Polymerase 
The Taq DNA Polymerase from Thermus aquaticus possesses a 5 !–3 ! DNA-dependent DNA 
polymerase activity and a 5 !–3’ exonuclease activity. The extension rate of Taq is 1 kb per 
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minute. Depending on the length of the product, the extension time of the PCR cycle 
needed to be adjusted (e.g. 2 minutes for 2 kb). The annealing time was either calculated 
on the basis of the melting temperature (Tm) of the primers used (Ta = Tm – 5°C) or 
several annealing temperatures were tried out in parallel.  
 
Reaction mix    PCR Program  
Volume Stock Final conc.   Time Temp. 
1 µl Template (undil., 1:10, 1:100) -   5’ 95°C 
5 µl 10x buffer 1x  20” 95°C 
1 µl dNTP mix (10 mM) 0.2 mM  45” x °C 
1 µl Forward primer (10 µM) 0.2 µM  
2
9
 c
yc
le
s 
x ” 72°C 
1 µl Reverse primer (10 µM) 0.2 µM   6’ 72°C 
40.5 µl dH2O -   " 4°C 
0.5 µl Taq DNA Polymerase (5 U/µl) 2.5 U     
50 µl Total volume      
5.3.3.2 PCR using Phusion™ DNA Polymerase 
The Phusion™ DNA Polymerase from Pyrococcus is a proofreading polymerase with 3’-5’ 
exonuclease activity (error rate: 4.4 x 10-7). The extension time is 15 seconds per kb. 
Depending on the length of the product, the extension time in the PCR cycle needed to 
be adjusted (e.g. 30” for 2 kb). The annealing time was either calculated on the basis of 
the melting temperature of the primers used (Ta = Tm – 5°C) or several annealing 
temperatures were tried out in parallel.  
 
Reaction mix    PCR Program  
Volume Stock Final conc.   Time Temp. 
1 µl Template (undil., 1:10, 1:100) -   2’ 98°C 
10 µl 5x buffer 1x  30” 98°C 
1 µl dNTP mix (10 mM) 0.2 mM  45” x °C 
0.5 µl MgCl2   
2
9
 c
yc
le
s 
x ” 72°C 
1 µl Forward primer (10 µM) 0.2 µM   10’ 72°C 
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1 µl Reverse primer (10 µM) 0.2 µM   " 4°C 
35 µl dH2O -     
0.5 µl Phusion™ DNA Polymerase (2 U/µl) 1 U     
50 µl Total volume      
5.3.4 Sequencing analysis 
To check cloned fragments or vectors 500 ng of DNA together with corresponding 
sequencing primers (see section 4.6.3) was sent to the in-house sequencing department. 
Sequence files were obtained online in ABI-format and analyzed using “4Peaks”.  
5.4 RNA techniques 
5.4.1 RNA polyacrylamide gel electrophoresis 
For RNA gels, special glass plates, combs and spacers were cleaned with detergent and 
70% ethanol. The plates were dried and siliconized using Sigmacote® to facilitate 
removal of the gel from the glass plates after running. For processing assays, 0.4 mm 
spacers were used, for labeling and purification gels 1 mm spacers. Prior to loading the 
gel, sample wells were rinsed using a syringe filled with 0.5x TBE buffer to remove traces 
of urea. Volumes and reagents for casting gels are given in Table 5. RNA samples to be 
analyzed were mixed with 2x STOP buffer, denaturated (95°C, 1’) and loaded into the 
sample wells. The gel was run in a vertical gel electrophoresis chamber in 0.5x TBE. For 
0.4 mm gels, pre-run was at 30 W for 60 minutes, 1 mm gels were pre-run at 10 W for 10 
minutes. Electrophoresis was stopped when the bromophenol blue marker reached the 
end of the gel. 
 
  6% 8% 10% 12% 15% 20% 
Concentrate 7.2 ml  12 ml  18 ml 24 ml 
Diluent 20 ml  15 ml  9 ml 3 ml 
Buffer 3 ml  3 ml  3 ml 3 ml 
10% APS 240 µl  240 µl  240 µl 240 µl 
TEMED 12 µl  12 µl  12 µl 12 µl 
0
.4
 m
m
 g
el
 
Volume 30 ml  30 ml  30 ml 30 ml 
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Concentrate 12 ml 16 ml 20 ml 24 ml 20 ml 40 ml 
Diluent 33 ml 29 ml 25 ml 21 ml 15 ml 5 ml 
Buffer 5 ml 5 ml 5 ml 5 ml 5 ml 5 ml 
10% APS 400 µl 400 µl 400 µl 400 µl 400 µl 400 µl 
TEMED 20 µl 20 µl 20 µl 20 µl 20 µl 20 µl 
1
 m
m
 g
el
 
Volume 50 ml 50 ml 50 ml 50 ml 50 ml 50 ml 
        
Concentrate 17 ml  28 ml  42 ml 56 ml 
Diluent 46 ml  35 ml  21 ml 7 ml 
Buffer 7 ml  7 ml  7 ml 7 ml 
10% APS 560 µl l 560 µl  560 µl 560 µl 
TEMED 28 µl  28 µl  28 µl 28 µl 
L
o
n
g 
ge
ls
 
Volume 70 ml  70 ml  70 ml 70 ml 
Table 5: Reagents and volumes needed for RNA polyacrylamide gels. 
5.4.2 Generation of miRNA precursor probes 
5.4.2.1 in vitro transcription by T7 RNA polymerase 
Substrates for the processing assay were generated by in vitro transcription using the 
AmpliScribe™ T7-Flash™ Transcription Kit. To create the transcription template, DNA 
sequences of the desired miRNA precursors obtained from the miRNA registry miRBase 
were fused at their 5-end to the T7 minimum consensus promoter sequence 
(TTAATACGACTCACTATAGG). For in vitro transcription, the following reaction 
components were combined at room temperature in the order given and incubated 
(37°C, 90’). 
 
Volume Reagent Final concentration 
x µl RNase-free water - 
1 µg Linearized template DNA 50 ng/µl 
2 µl AmpliScribe™ T7-Flash 10x Reaction Buffer 1x 
1.8 µl 100 mM ATP 9 mM 
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1.8 µl 100 mM CTP 9 mM 
1.8 µl 100 mM GTP 9 mM 
1.8 µl 100 mM UTP 9 mM 
2 µl 100 mM DTT 10 mM 
2 µl AmpliScribe™ T7-Flash Enzyme Solution - 
20 µl Total volume  
5.4.2.2 Ethanol precipitation of RNA transcripts 
After in vitro transcription and prior to the purification of the RNA transcripts on 
polyacrylamide gels, the miRNA precursors were precipitated from the enzyme-buffer 
solution using 100% ethanol to reduce salt content and by this avoid formation of a 
smearing salt bubble on the polyacrylamide gel. The precipitation was performed 
according as follows: the volume of the sample was adjusted to 300 µl with dH2O. 1/10 
volume of 3 M sodium acetate (NaOAc) and 3 volumes of -20°C cold 100% ethanol were 
added. RNA precipitated at -20°C for at least 60 minutes. Then, the sample was 
centrifuged at 4°C for 30 minutes at maximum speed (16 000 x g) and the supernatant 
was removed. To wash the pellet, 1 ml of 70% ethanol was added and after inverting the 
tube centrifugation was repeated. The supernatant was removed to let the pellet dry. 40 µl 
of 1x STOP buffer were added to resuspend the pellet. The mixture was denaturated 
(95°C, 1’) and then loaded on a 1 mm 8% polyacrylamide gel.  
5.4.2.3 PAGE-purification of RNA transcripts 
Transcribed RNAs can be purified using gel or column purification, depending on the 
heterogeneity of the sample. If other transcripts than desired exist in the sample, gel 
purification is preferred as this allows excising only the correct band after electrophoretic 
separation. 
The miRNA precursors were separated on an 8% denaturing polyacrylamide gel with 1 
mm slots (for conditions see 5.4.1). RNA was detected by taking advantage of the UV epi-
illumniation effect of RNA strands: the gel was placed between a handheld lamp with a 
wavelength of 254 nm and a white sheet of paper. RNA transcripts in the gel absorbed 
the emitted UV rays, being visualized on the sheet of paper. Transcripts of correct size 
were marked and excised from the gel using scalpels. The gel slices were incubated in 300 
µl of 0.3 M NaCl overnight in a shaker (4°C, 1000 rpm) to elute the transcripts. The 
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eluate was precipitated using 3 volumes of -20°C cold 100% ethanol at -20°C for at least 
60 minutes. Then, the sample was centrifuged at 4°C for 30 minutes at maximum speed 
(16 000 x g) and the supernatant was removed. To wash the pellet, 1 ml of 70% ethanol 
was added and after inverting the tube centrifugation was repeated. The pellet was air-
dried and resuspended in an appropriate volume of TN buffer to a final concentration of 
10 pmol/µl (10 µM). The actual concentration of the transcript was determined by 
photometrical measurement at 260/280 nm using SmartSpec™ Plus (Bio-Rad).  
5.4.2.4 Dephosphorylation of miRNA precursors 
5’-end labeling of miRNA precursors with the radioactive isotope $-32P-ATP enables 
detection in processing assays. For this, the RNA transcripts were first dephosphorylated 
at their 5’-ends with alkaline phosphatase (20 U/µl, Roche) using 1 U per pmol RNA at 
50°C for 60 minutes. To remove the enzyme from the reaction afterwards, an RNA 
extraction was performed. 
5.4.2.5 Phenol/chloroform/isoamyl alcohol extraction of RNA transcripts 
The dephosphorylation reaction was adjusted to 300 µl with dH2O and extracted once 
with phenol/chloroform/isoamyl alcohol (pH 4.0, P:C:I = 25:24:1) and once with 
chloroform/isoamyl alcohol (C:I = 24:1), followed by ethanol precipitation according to 
the instructions given in 5.4.2.2. The pellet was resuspended in an appropriate volume of 
dH2O to a final concentration of 10 pmol/µl.  
5.4.2.6 Labeling of miRNA precursors with radioactive $-32P-ATP 
For the 5’-end labeling, the following reagents and amounts were combined at RT: 
 
Volume Reagent Final concentration 
1 µl (= 10 pmol) miRNA precursor 1 pmol/µl 
1 µl 10x T4 PNK buffer 1x 
1.5 µl 32P- $ -ATP  
6.4 µl dH2O - 
0.1 µl T4 PNK  
10 µl Total volume  
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After incubating the reaction mix for 25 minutes at 37°C, the reaction was quenched by 
adding 1 µl of 100 mM cold ATP. After 5 minutes the reaction was stopped by adding 11 
µl of 2x STOP-buffer. The radioactively labeled transcripts were then purified on a 
polyacrylamide gel according to the instructions given in section 5.4.1. The correct band 
was detected by autoradiography on X-ray films (Kodak) and excised using scalpels. 
Elution of the 5’-end labeled miRNA precursors was performed as described before 
(5.4.2.3). The purified transcripts were resuspended using TN buffer to a final 
concentration of 100 nM, denatured (95°C, 1’), reannealed (37°C, 60’) and stored at -
20°C.  
5.5 Functional assays 
5.5.1 Dicer processing assay for miRNA precursors 
This assay was developed to monitor Dicer activity on specific miRNA precursors 
(Leuschner 2007). In general, 0.0156 µl recombinant Dicer enzyme (rDcr, 1 U/µl) was 
added to 2.5 µl 2x reaction buffer. The reaction mix was incubated 10 minutes at 37°C 
with 1 µl of a 1:500 diluted proteinase K solution (stock: 14 mg/ml) to proteolytically 
activate the rDcr enzyme. 2.5 µl of the enzyme solution were mixed with 0.5 µl substrate 
and 2 µl dH2O, RNAi-Buffer or SRP9/14-depleted cell extracts to check for Dicer 
activity. The reaction was stopped after 5 minutes at 37°C by adding 5 µl 2x STOP-
buffer. RNA was denatured (95°C, 1’) and loaded on a 15% polyacrylamide gel (0.4 mm 
slots, 30 W) to separate the cleavage products. The gel was exposed over night using X-
ray films and signals detected using Typhoon TRIO. 
5.5.2 Processing assay for miRNA precursors using recombinant protein 
To analyze the effect of SRP9, SRP14, both or SRP9-myc-14 on Dicer processing 2.5 µl 
pre-activated rDcr in 2x reaction buffer, 0.5 µl substrate and 2 µl of the recombinant 
candidate protein in varying concentrations were mixed (SRP9, SRP14: undiluted, 1:5, 
1:10, 1:50, 1:100; SRP9-myc-14: undiluted, 1:3, 1:9, 1:27, 1:81, 1:243, 1:729). The 
incubation procedure and electrophoretic separation was performed as stated in section 
5.5.1. 
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5.5.3 Processing assay for miRNA precursors using SRP9/14 and BSA 
To eliminate putative unspecific RNA-binding effects of proteins, 0.5 µl of a 10 mg/ml 
bovine serum albumin solution were incubated with 2 µl SRP9/14, 0.5 µl substrate, and 3 
µl 2x reaction buffer containing 0.0156 µl pre-activated rDcr for 5 minutes. The reaction 
was stopped by adding 6 µl 2x STOP-buffer, denatured (95°C, 1’) and loaded on a 15% 
polyacrylamide gel (0.4 mm slots, 30 W, see section 5.4.1).  
5.6 Preparative protein techniques 
5.6.1 Expression and purification of recombinant protein 
BL21 is the most commonly used bacterial strain for expression of recombinant proteins. 
In this study, Rosetta™ E. coli (Novagen), a strain derived from BL21, but better suited for 
expressing eukaryotic proteins, was used for expression of human recombinant proteins. 
Rosetta bacteria translate mRNA from eukaryotic genes more efficiently than BL21 as 
they possess additional tRNAs complementary to eukaryotic codons, which are usually 
rarely found in bacterial genes. 
5.6.1.1 Transformation of plasmid into E. coli 
50 ng of the expression vector pDEST17-SRP9, pDEST17-SRP14 or pDEST17-SRP9-
myc-14 transformed in 10 µl chemically-competent Rosetta™ E. coli according to the 
transformation protocol in section 5.2.3.  
5.6.1.2 Expression of recombinant protein 
To set up a pre-culture, one Rosetta™ colony from a freshly streaked LB plate was 
inoculated in 20 ml LB medium plus antibiotics and grown until OD600 was higher than 3 
(5-7 hours). The pre-culture was then diluted in 400 ml LB without resistances to an 
OD600 of 0.1. Cells were grown until OD600 of 0.4 was reached, then cooled down to 
20°C for 30 minutes. For later examination, a 1 ml aliquot from the cell suspension was 
taken at this step and spinned down (2’, 3400 x g, RT). The pellet was resuspended in 50 
µl 1x Sample Buffer and denaturated (95°C, 5’). Induction of protein expression was 
performed by adding IPTG to a concentration of 0.1 mM and incubating at 20°C over 
night in a shaker. Again a 1 ml aliquot was taken from the induced culture and treated in 
the same way as before. 
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5.6.1.3 Hypotonic lysis 
The cells were harvested using a Sorvall centrifuge (5600 x g, 20’, 4°C). The pellet was 
resuspended in 30 ml cold 1x PBS and transferred to a 50 ml falcon tube. The cells were 
again harvested (15’, 2000 x g, 4°C). The washed pellet was resuspended in 400 ml 
Washbuffer His-tag + 1/2 tab of protease inhibitor mix and transferred into 50 ml Sorvall 
centrifuge tubes. Lysis of the cells was supported by sonication of cell membranes 
performed in the coldroom (6 x 15”, 30” pause in between). To remove the cell debris, 
sonicated cells were spinned down (30’, 16.000 x g, 4°C).  
5.6.1.4 Affinity chromatography 
2 ml of the Ni-NTA beads were equilibrated by spinning down (3’, 500 x g, 4°C) and 
washing twice with Washbuffer His-tag. To remove the supernatant, a special Pasteur 
pipette coupled to a vacuum pump was used. After the first washing step, the beads were 
separated into two 15 ml falcons to provide more space for the bacterial extract. After 
centrifugation of the sonicated cells, 30 µl of the supernatant and a bit of the pelleted cell 
debris were taken as an aliquot. The remaining lysate was transferred onto the two 
fractions of Ni-NTA beads and the tubes were mounted on a rotation wheel in the cold 
room for 90 minutes. Care had to be taken to avoid spuming. The beads were harvested 
by centrifugation (3’, 500 x g, 4°C). At each of the next steps, an aliquot of 30 µl was 
taken. The beads were washed with 30 ml Washbuffer His-tag by vortexing and 
centrifuging (3’, 500 x g, 4°C). For the second wash, 4 ml Washbuffer His-tag + 25 mM 
imidazole was added to each of the falcon tubes, vortexed, pooled and put onto a column. 
After settling of the slurry the valve was opened and the flow-through collected. Then the 
column was washed a third time with 10 ml Washbuffer His-tag + 50 mM imidazole and 
a fourth time with 10 ml Washbuffer His-tag + 100 mM imidazole, For the elution, 1 ml 
elution buffer with 300 mM imidazole was added on top of the column. The beads were 
vortexed and let settle, then the valve was opened and the first eluate collected. For the 
second elution the procedure was repeated. A small aliquot was also taken from the beads 
for later analysis. 
5.6.1.5 Dialysis of purified proteins 
Due to the high imidazole concentration of the eluates (300 mM), the purified protein 
samples had to be dialysed. The bottom of a Petri dish was filled with dialysis buffer 
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(RNAi buffer). Using forceps, Millipore membrane filter discs were floated on the surface 
of the buffer. Small volumes of samples (20-40 µl) were pipetted onto the membranes and 
dialyzed for 60 minutes. Then the samples were removed from the membrane using 
pipettes and used for analysis. 
5.6.2 Determination of protein concentration 
5.6.2.1 Bradford assay 
The protein concentration of cell lysates or eluates was measured using Bradford Protein 
Assay according to the manufacturer's instructions. 800 µl dH2O plus 1 µl sample were 
added to 200 µl Bradford solution in a plastic cuvette. For generation of the standard 
curve, 0, 2, 6 or 10 µl of a 1 mg/ml BSA solution were mixed with 800 µl dH2O + 1 µl 
Washbuffer His-tag. The absorption of the protein-Bradford solution was measured 
immediately using a spectrophotometer exciting at a wavelength of 595 nm.  
5.7 Analytical protein techniques 
5.7.1 SDS polyacrylamide gel electrophoresis and Western blotting 
5.7.1.1 Conventional one-dimensional gels 
SDS-PAGE was performed on either 9 x 9 cm or 12 x 9 cm gels, comprising a 5% 
stacking gel (pH 6.8) and a 12% or 15% separation gel (pH 8.8). Gels were casted 
according to Table 6, TEMED and APS were added in the last step. After pouring the 
separation gel, 1 ml of butanol was added on top to avoid the formation of bubbles. 
Protein samples were mixed with 5x sample buffer, denatured (95°C, 5’) and loaded into 
the wells with a protein marker.  
 
Separation gels    
    
15% For 10 ml  For 30 ml For 50 ml 
Separation Buffer 4x 2.5 ml 7.5 ml 12.5 ml 
30/0.8% acryl/bisacryl 5 ml 15 ml 25 ml 
dH2O 2.5 ml 7.5 ml 12.5 ml 
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10% APS 50 µl 150 µl 250 µl 
TEMED 5 µl 15 µl 25 µl 
    
12% For 10 ml  For 30 ml For 50 ml 
Separation Buffer 4x 2.5 ml 7.5 ml 12.5 ml 
30/0.8% acryl/bisacryl 4 ml 12 ml 20 ml 
dH2O 3.5 ml 10.5 ml 17.5 ml 
10% APS 50 µl 150 µl 250 µl 
TEMED 5 µl 15 µl 25 µl 
    
10% For 10 ml  For 30 ml For 50 ml 
Separation Buffer 4x 2.5 ml 7.5 ml 12.5 ml 
30/0.8% acryl/bisacryl 3.33 ml 10 ml 16.6 ml 
dH2O 4 ml 12 ml 20 ml 
10% APS 50 µl 150 µl 250 µl 
TEMED 5 µl 15 µl 25 µl 
    
7.5% For 10 ml  For 30 ml For 50 ml 
Separation Buffer 4x 2.5 ml 7.5 ml 12.5 ml 
30/0.8% acryl/bisacryl 2.5 ml 7.5 ml 12.5 ml 
dH2O 4.93 ml 14.8 ml 24.7 ml 
10% APS 50 µl 150 µl 250 µl 
TEMED 5 µl 15 µl 25 µl 
    
Stacking gel (5%)    
 For 10 ml  For 30 ml For 50 ml 
Stacking Buffer 8x 1.25 ml 2.5 ml 5 ml 
30/0.8% acryl/bisacryl 1.66 ml 3.35 ml 6.7 ml 
dH2O 7 ml 14 ml 28 ml 
10% APS 50 µl 100 µl 200 µl 
TEMED 10 µl 20 µl 40 µl 
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Table 6: Reagents and volumes needed for casting SDS-PAGE gels.  
 
Electrophoresis was carried out at 20 mA per gel in SDS-PAGE running buffer until the 
bromophenol blue marker reached the stacking gel, followed by separation at 30 mA per 
gel for 60 minutes or until the bromophenol blue marker reached the end of the gel. The 
glass plates were then diassembled, the stacking gel cut off and the gel stained with 
Coomassie or prepared for Western Blotting. 
5.7.1.2 Pre-cast one-dimensional gradient gels 
When available, Novagen® 4-20% Tris-glycine gradient gels (1 mm, 15 wells) were used 
for separation of proteins. Electrophoresis was carried out in SDS-PAGE running buffer 
at 20 mA for samples in the stacking gel and 30 mA afterwards until the bromophenol 
blue marker reached the end of the gel. 
5.7.2 Staining of SDS-PAGE gels 
5.7.2.1 Conventional Coomassie staining 
After disassembly of the gel, the stacking gel was removed and the separation gel 
immersed in Coomassie staining solution for 8 minutes. To destain, the gel was incubated 
in Coomassie destaining solution until single bands could be discriminated (30 minutes). 
The destaining solution was exchanged until the signal-background relation was good (up 
to one day). To wash away traces of methanol from the destaining solution, the gel was 
then incubated in dH2O and dried if necessary. 
5.7.2.2 Drying of stained SDS-PAGE gels 
For drying of the stained gel, it was sandwiched between Whatman paper (two layers) and 
Saran wrap and dried for 90 minutes at 80°C using a vacuum pump-coupled gel dryer.  
5.7.3 Western blot analysis 
After electrophoretic separation, the gel was immersed in Semidry-Blot-Buffer. For 
blotting, 2x 3 Whatman papers and a PVDF membrane of gel size were prepared and 
moistened with Semidry-Blot-Buffer. After assembly of the blotting sandwich (3 Whatman 
papers + membrane + gel + 3 Whatman papers) the gel was blotted for 1.5 hours least. 
The power was dependent on gel size: cm2 x 0.8 = mA. Then the membrane was blocked 
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one hour in 4% non-fat dry milk in PBST at RT (or at 4°C over night), followed by 
incubation with the first antibody in 4% milk-PBST for one hour at RT. The membrane 
was washed three times with milk-PBST (2x 5 minutes, 1x 10 minutes) and incubated 
with the corresponding HRP-coupled secondary antibody in PBST for one hour at RT. 
After three washing steps with PBST (2x 5 minutes, 1x 10 minutes) the membrane was 
developed using Enhanced Chemi-Luminescence Kit and exposed on Amersham 
Hyperfilm™ ECL films.  
5.8 Expression cloning using Gateway® Technology 
Gateway® cloning is a technology developed by Invitrogen that enables the researcher to 
shuttle the gene of interest into various expression and functional analysis systems. Time-
consuming and/or low-efficiency steps of traditional cloning methods are avoided by 
using an entry clone that performs site-specific recombination with the desired destination 
vector (Figure 17). 
 
 
Figure 17: Gateway® cloning. (A) Overview of possible genes sources and target vectors for Gateway® 
cloning. After cloning the desired gene into an entry vector shuttling into various destination vectors is 
facilitated by site-specific recombination. (B) Top: Three options exist to generate the entry vector. In this 
study, the entry vector was cloned using aattB-flanked PCR product and the donor vector pDONR201. 
Bottom: Once the gene of interest is cloned into the entry vector, gene shuttling into different made possible 
by clonase enzymes. Figure modified and adapted from Invitrogen. 
(http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cloning/Gateway-Cloning). 
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5.8.1 Cloning of SRP9 and SRP14 
A 2-step PCR protocol was employed to clone SRP9 (261 bp) and SRP14 (333 bp) into 
the entry clone pDONR201. Both genes were amplified from RIKEN library clones 
9530033C02 and F8301020O9, respectively. The following template-specific primers 
extended by the generic recombination sites attB1 and attB2 (12 nt) were used. 
General scheme:  
attB1: 5’-AA AAA GCA GGC TNN-(template-specific sequence)-3’ 
attB2: 5’-A GAA AGC TGG GTN-(template-specific sequence)-3’ 
Designed primers: 
SRP9-fwd-attB1: AAAAAGCAGGCTCAATGCCTCAGTTCCAGACCTGGG 
SRP9-rev-attB2: AGAAAGCTGGGTCTCATTCTGTTTCCATAGTGACATTGCGG 
SRP14-fwd-attB1: AAAAAGCAGGCTCAATGGTGTTGCTCGAGAGCGAGC 
SRP14-rev-attB2: AGAAAGCTGGGTCTCACTGTGCTGGTTTGCTCTTCTTAC 
Legend: attB1 sites, attB2 sites, template-specific sequence, start codon, stop codon 
5.8.1.1 Phusion PCR step 1 
For SRP9 and SRP14, the extension time was 15”, two annealing temperatures, 50°C 
and 56°C, were specified in parallel. 
Reaction mix    PCR Program  
Volume Stock Final conc.   Time Temp. 
1 µl RIKEN template (undil., 1:10, 1:100) -   2’ 98°C 
10 µl 5x buffer 1x  20” 98°C 
1 µl dNTP mix (10 mM) 0.2 mM  45” x °C 
0.5 µl MgCl2   
2
9
 c
yc
le
s 
x ” 72°C 
1 µl Forward primer (10 µM) 0.2 µM   10’ 72°C 
1 µl Reverse primer (10 µM) 0.2 µM   " 4°C 
35 µl dH2O -     
0.5 µl Phusion™ DNA Polymerase (2 U/µl) 1 U     
50 µl Total volume      
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The product generated in PCR step 1 was amplified in the second 2-phased PCR using 
universal attB adapter primers, which align to the attB1 and attB2 site attached to the 
cloned genes. 
5.8.1.2 Phusion PCR step 2 
Reaction mix     PCR Program  
Volume Stock Final conc.   Time Temp. 
1 µl Step 1 product (undil., 1:10, 1:100) -   2’ 98°C 
10 µl 5x buffer 1x  20” 98°C 
1 µl dNTP mix (10 mM) 0.2 mM  30” 45°C 
0.5 µl MgCl2   
1
st
 p
h
a
se
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5
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s 
x ” 72°C 
1 µl Universal attB1 adapter primer (10 µM) 0.2 µM  20” 98°C 
1 µl Universal attB2 adapter primer (10 µM) 0.2 µM  30” 55°C 
35 µl dH2O   
2
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d
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: 
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x ” 72°C 
0.5 µl Phusion™ DNA Polymerase (2 U/µl)    10’ 72°C 
50 µl Total volume    " 4°C 
 
The amplified PCR products from step 2 contain attB-sites capable of recombination with 
attP-sites. In the BP reaction, Clonase catalyses the recombination of attB-flanked PCR 
products with the donor vector pDONR201.  
5.8.1.3 BP reaction 
 
 
The reaction mix was incubated for 60 minutes at 25°C. Then, the total reaction volume 
was transformed into competent E. coli and plated out on LBKan plates (pDONR201 
Volume Reagent Final conc. 
1 µl attB-PCR product (40-100 fmol) - 
1 µl pDONR201 vector (150 ng/µl), KanR 15 ng 
2 µl 5x BP Clonase Reaction Buffer 1x 
2 µl Clonase - 
4 µl TE Buffer - 
10 µl Total volume  
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carries a kanamycin resistance). A positive clone was selected for the second 
recombination step, the LR reaction, which allows shuttling of SRP9 and SRP14 from the 
pDONR clone into the chosen destination vector pDEST17.  
5.8.1.4 LR reaction and transformation 
Volume Reagent Final amount 
- pDONR201-SRP9/14 25-75 ng  
0.5 µl pDEST17 (150 ng/µl), AmpR 15 ng 
ad 4 µl TE buffer - 
1 µl Clonase II LR Enzyme Mix - 
5 µl Total volume  
 
60 ng of pDONR vectors were used for the LR reaction. After incubation (25°C, 60’) 0.5 
µl Proteinase K was added for 10 minutes at 37°C to stop Clonase II activity. The 
reaction mix was then transformed in E. coli and plated out on LBAmp. Positive clones 
were confirmed by sequencing and named pDEST17-SRP9 and pDEST17-SRP14. 
Expression of recombinant proteins is described in section 5.6.1. 
5.8.2 Cloning of SRP9-myc-14 
Cloning of the gene expressing the fusion protein SRP9-myc-14 involved two main parts:  
1) Ligation of the genes for SRP9, SRP14, and the myc-tag, followed by 
amplification of the ligation product, and a 
2) 2-step PCR protocol based on Gateway® cloning as described in section 5.8.1. 
5.8.2.1 Primer design and cloning the genes 
SRP9 and SRP14 were first amplified from RIKEN clones 9530033C02 and 
F8301020O9, respectively, using the following primers: 
 
SRP9-fwd-attB1: AAAAAGCAGGCTCAATGCCTCAGTTCCAGACCTGGG 
SRP9-rev-EcoRI: CCGG’AATTCTGTTTCCATAGTGACATTGCGG 
SRP14-fwd-BamHI: CGCG’GATCCCATGGTGTTGCTCGAGAGCGAGC 
SRP14-rev-attB2: AGAAAGCTGGGTCTCACTGTGCTGGTTTGCTCTTCTTA 
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Legend: attB1 site, attB2 site, template-specific primer, start codon, restriction site, stop 
codon 
 
Annealing temperature was 56°C, extension time 15”.  
 
Reaction mix    PCR Program  
Volume Stock Final conc.   Time Temp. 
1 µl RIKEN clone (undil., 1:10, 1:100) -   2’ 98°C 
10 µl 5x buffer 1x  20” 98°C 
1 µl dNTP mix (10 mM) 0.2 mM  45” 56°C 
0.5 µl MgCl2   
2
9
 c
yc
le
s 
15” 72°C 
1 µl Forward primer (10 µM) 0.2 µM   10’ 72°C 
1 µl Reverse primer (10 µM) 0.2 µM   " 4°C 
35 µl dH2O -     
0.5 µl Phusion™ DNA Polymerase (2 U/µl) 1 U     
50 µl Total volume      
 
The PCR product were then digested using EcoRI for SRP9 and BamHI for SRP14 90 
minutes at 37°C. 
 
Volume Reagent Final conc.  Volume Reagent Final conc. 
10 µl SRP9 PCR product -  10 µl SRP14 PCR product - 
2 µl 10x EcoRI-buffer 1x  2 µl 10x Buffer 3 1x 
0.4 µl EcoRI -  0.4 µl BamHI - 
7.6 µl dH2O   2 µl 10x BSA 1x 
20 µl Total volume   5.6 µl dH2O  
    20 µl Total volume  
 
The reaction mix was loaded on a 2% agarose gel and eluted according to the 
manufacturer’s instructions in 30 µl elution buffer using QIAquick Gel Extraction Kit.  
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DNA concentrations: SRP9 = 3.7 ng/µl, SRP14 = 5.4 ng/µl.  
5.8.2.2 Preparation of the linker 
The linker (myc-tag) was generated from two oligo sequences: 
Sense (LNK-SE):  
5’-AATTGGGCGGCGAGCAGAAGCTGATCAGCGAGGAGGACGACAGCCGGGGC-3’ 
Antisense (LNK-AS):  
5’-GATCGCCCCGGCTGTCGTCCTCCTCGCTGATCAGCTTCTGCTCGCCGCCC-3’ 
Legend: BamHI, EcoRI, myc-tag sequence 
First step was to phosphorylate both linker strands separately at the 5’-end. 
 
Volume  Final concentration 
1 µl Oligo (100 mM) 100 pmol 
1 µl ATP (100 mM) 10 mM 
1 µl 10x PNK buffer 1x 
0.5 µl Polynucleotide Kinase - 
6.5 µl dH2O - 
10 µl Total volume  
 
The reaction mix was incubated at 37°C for 60 minutes. Then both samples LNK-SE 
and LNK-AS were mixed an annealed one minute at 95°C. 100 fmol of double-stranded 
linker was ligated with total amount of eluted SRP9 and SRP14 at 16°C over night.  
5.8.2.3 Ligation of linker with SRP9/14 
 
Volume  Final concentration 
25 µl SRP9 (EcoRI) -- 
25 µl SRP14 (BamHI) - 
1 µl ds LNK 100 fmol- 
6 µl 10x T4 ligase buffer 1x 
2 µl T4 ligase - 
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1 µl dH2O  
60 µl Total volume  
 
5.8.2.4 Phusion PCR step 1 
The ligation mix was amplified using Phusion™ PCR to increase the amount of the fusion 
construct.  
 
Reaction mix    PCR Program  
Volume Stock Final conc.   Time Temp. 
1 /5 / 10 µl Ligation mix -   2’ 98°C 
10 µl 5x buffer 1x  20” 98°C 
1 µl dNTP mix (10 mM) 0.2 mM  45” 56°C 
0.5 µl MgCl2   
2
9
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le
s 
15” 72°C 
1 µl SRP9-fwd-attB1 0.2 µM   10’ 72°C 
1 µl SRP14-rev-BamHI 0.2 µM   " 4°C 
x µl dH2O -     
0.5 µl Phusion DNA Polymerase (2 U/µl) -     
50 µl Total volume      
 
The band of expected size (approximately 650 bp) was eluted from the gel (c = 30 ng/µl) 
and used as a template for the second step of the Gateway® cloning protocol. 
5.8.2.5 Phusion PCR step 2 
Reaction mix     PCR Program  
Volume Stock Final conc.   Time Temp. 
1 µl SRP9-myc-14 (undil., 1:10, 1:100) -   2’ 98°C 
10 µl 5x buffer 1x  20” 98°C 
1 µl dNTP mix (10 mM) 0.2 mM  30” 45°C 
0.5 µl MgCl2   
1
st
 p
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se
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30 ” 72°C 
1 µl Universal attB1 adapter primer (10 µM) 0.2 µM  
2
n
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s 20” 98°C 
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1 µl Universal attB2 adapter primer (10 µM) 0.2 µM  30” 55°C 
35 µl dH2O   
 
30 ” 72°C 
0.5 µl Phusion™ DNA Polymerase (2 U/µl)    10’ 72°C 
50 µl Total volume    " 4°C 
 
The amplified PCR products were recombinated into pDONR201 as before (BP 
reaction). 
5.8.2.6 BP reaction 
Volume  Final concentration 
1 µl attB-PCR product (40-100 fmol) - 
1 µl pDONR vector (150 ng/µl) 15 ng/µl 
2 µl 5x BP Clonase Reaction Buffer 1x 
2 µl Gateway® BP Clonase® II enzyme mix  
4 µl TE Buffer  
10 µl Total volume  
 
The reaction mix was incubated for 60 minutes at 25°C. Then, the total reaction volume 
was transformed into competent E. coli and plated out on LBKan plates. Sequencing 
analysis of these clones showed that none of them included the linker. Therefore, the 
cloning strategy was modified. 
5.8.3 New cloning strategy for SRP9-myc-14 
Amplified SRP9 and SRP14 were again digested with EcoRI and BamHI, respectively. 
Fragments were purified from agarose gels (30 µl) and yielded 7 ng/µl (SRP9) and 16 
ng/µl (SRP14).  
The linker strands were separately phosphorylated as before (5.8.2.2). Then the sense and 
antisense strand were subjected to phenol-chloroform-isoamylalcohol extraction using 
non-acid phenol to remove the polynucleotide kinase from the solution.  
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5.8.3.1 Phenol-chloroform-isoamyl alcohol extraction of DNA fragments 
290 µl were added to the reaction to yield 300 µl solution in total. 1 volume of non-acid 
PCR was added and the tube shaken vigorously. After 5 minutes centrifugation at 16 000 
x g the upper aqueous phase was pipetted into a new tube. 1 volume chloroform-isoamyl 
alcohol was added and the tube shaken vigorously. After 5 minutes centrifugation at 16 
000 x g the upper phase was again pipetted into a new tube (~290 µl). 1/10 volume of 3 
M NaOAc (29 µl) was added and the tube was inverted several times. 3 volumes of -20°C 
EtOH abs. was mixed with the solution and incubated 60 minutes least at -20°C. Then 
the sample was centrifuged 30 minutes (4°C, 16 000 x g). The supernatant was removed 
and 1 ml 70% EtOH added. The tube was inverted twice and again centrifuged for 30 
minutes (4°C, 16 000 x g). After removal of the supernatant the pellet was air-dried and 
then resuspended in TE buffer (80 µl for ~ 80 pmol; 20% loss of DNA amount).  
5.8.3.2 Preparation of the linker 
Next, two different linkers were generated, only one strand of the duplex being 
phosphorylated as follows: 
1) Phosphorylated LNK-AS + LNK-SE 
2) Phosphorylated LNK-SE + LNK-AS 
The singles-stranded DNA fragments were denatured (95°C, 1’) and hybridized (37°C, 
20’). Then, ligation was performed with SRP9 and SRP14 according to the following 
scheme: 
1 pmol SRP9 + 3 pmol LNK1 
1 pmol SRP14 + 3 pmol LNK2 
 
Volume  Final conc.  Volume  Final conc. 
22 µl SRP9 (EcoRI) 1 pmol  12.5 µl SRP14 (BamHI) 1 pmol 
3 µl LNK1 3 pmol  3 µl LNK2 3 pmol 
3 µl 10x T4 ligase buffer 1x  0.4 µl 10x T4 ligase buffer 1x 
1 µl dH2O   10.5 µl dH2O 1x 
30 µl Total volume   30 µl Total volume  
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The reaction was incubated for 120 minutes at 37°C, then denatured (95°C, 1’) and 
annealed (37°C, 20’).  
For the second ligation, 4µl 10x T4 ligation buffer, 2 µl T4 ligase and 34 µl dH2O were 
mixed with the SRP9- and SRP14-solutions yielding 100 µl and incubated over night at 
16°C.  
5.8.3.3 Phusion PCR step 1 
Phusion™ PCR was performed on the ligation mix using the primers for step 1 of 
Gateway® cloning.  
 
Reaction mix    PCR Program  
Volume Stock Final conc.   Time Temp. 
1 /5 /10 µl Ligation mix -   2’ 98°C 
10 µl 5x buffer 1x  30” 98°C 
1 µl dNTP mix (10 mM) 0.2 mM  45” 56°C 
0.5 µl MgCl2   
2
9
 c
yc
le
s 
15” 72°C 
1 µl SRP9-fwd (10 µM) 0.2 µM   10’ 72°C 
1 µl SRp14-rev (10 µM) 0.2 µM   " 4°C 
35 µl dH2O -     
0.5 µl Phusion™ DNA Polymerase (2 U/µl) 1 U     
50 µl Total volume      
 
The amplified product was checked on a 2% agarose gel and used for the second step. 
5.8.3.4 Phusion PCR step 2 
Reaction mix     PCR Program  
Volume Stock Final conc.   Time Temp. 
1 µl PCR product step 1 (undil, 1:10, 1:100) -   2’ 98°C 
10 µl 5x buffer 1x  20” 98°C 
1 µl dNTP mix (10 mM) 0.2 mM  30” 45°C 
0.5 µl MgCl2   
1
st
 p
h
a
se
: 
 
5
 c
yc
le
s 
30 ” 72°C 
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1 µl Universal attB1 adapter primer (10 µM) 0.2 µM  20” 98°C 
1 µl Universal attB2 adapter primer (10 µM) 0.2 µM  30” 55°C 
35 µl dH2O   
2
n
d
 p
h
a
se
: 
1
9
 c
yc
le
s 
30 ” 72°C 
0.5 µl Phusion™ DNA Polymerase (2 U/µl)    10’ 72°C 
50 µl Total volume    " 4°C 
 
BP reaction with the product from step 2 was performed as before (5.8.1.3) and after 
sequencing analysis the positive clone was subjected to LR reaction. pDEST17-SRP9-
myc-14 plasmids were transformed into Rosetta E. coli and used for expression of the 
recombinant protein.  
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7. Appendix 
7.1 Sequences 
SRP9 (RIKEN 9530033C02): 261 bp 
>ri|9530033C02|PX00112O12|1319 contigs=3 ver=1 seqid=23886 
GGTCTTTGCGCCGCCGGAGTGCAGCGCTGTGGGCGGTTGCGGGAGAGCGGCGGGCCGCCGGGGCGACAGCGC
CGTGACTCGCTTCGCGGCCTTGTTCCTCGCTGCCTGAAGCCACGATGCCTCAGTTCCAGACCTGGGAGGAGT
TCAGCCGGGCGGCCGAGAAGCTCTACCTGGCGGACCCCATGAAGGTACGGGTGGTTCTCAAATACAGGCATG
TTGATGGGAATTTGTGTATCAAAGTAACGGATGATCTAGTTTGTTTGGTGTACAGAACAGACCAAGCGCAAG
ACGTAAAGAAGATTGAGAAATTCCACAGTCAGTTAATGCGACTTATGGTGGCCAAGGAATCCCGCAATGTCA
CTATGGAAACAGAATGAATGGTTTGACATGAAGACGACTGTTCCGTTATTGGGAAGTAATCAGCTTTTGAAA
CTGAGAGTGTTGGGAAGGATATACTTACGTAATGGAGCTGTCAAAGCCGAGAGACCAGCCTGCGTCCTAAAG
TTTGCTTTAGAGAGTAGGAATGTCGGGGTTTCCAGTTAGAAAACCTTTATTTTTGGAAACGGAATAAAAATC
TCTTAGAAACTTTTGCAGATAATTTGATGTTGGGCAAATATATATAATTATTTTTTCTGGTAAATTCATGTC
AGTAATTTGTTGAAGAGTTAACAAGAAAAGGTCTTTTTAGATTGTGTCTAAGATGAAATAAAATGTAACTTT
TGCTGCAGTGGTATGTTTCTTTTGGAGTACAACATGTATGCCGTTTACAACACACACATGGTAACGGGGATC
ACATGCTCCATGGTGCGCACGATCCTGTGGTGTGAAGAGCAGGTCTGCTTTACCTTTCTTGCCAGGTTCAAA
CTGTGTTTTTAAATGGAAGGGATTTGTGGCATCCACTTGCTGAGCGGTGAACAGAGCGAGACGCAGTTGTGT
GTGCACCGGCAGATACTGACACTGATGGCTGACAGTGTGTGCGTCCTTCACGCCGGTGTGCAACGTACGCAG
TGTTTACTCAGTGTGGCTCCCGCCTCAGACTGAATTAAAGTATTACTATAGCATGCCTCTCAGAACTGCTAG
CTTCCTAATAAACCACAAATCCACCGTTTCTATGTAGCTTGTATTTGTAAAGTCTGAGTTTACCGTCTGAAT
GTAAAGTTCCGTGTTGTCCGCTCACGACGGAAGTGAAGAAGATACTGCATTCAAGTGTTTTTTGTAAAAGTT
TGTCATGGTGAATAACTTGAAATTTTTATTAGTTATAAGAATTTTAGTCTGTTTTAGAGGTCAGTAAATAAA
ATACAAGCATCCTGTTTTGTTG 
 
Amino acid sequence:  
MPQFQTWEEFSRAAEKLYLADPMKVRVVLKYRHVDGNLCIKVTDDLVCLVY
RTDQAQDVKKIEKFHSQLMRLMVAKESRNVTMETE 
NCBI accession number: NM_003133 
 
SRP14 (RIKEN F830102009): 333 bp 
>ri|F830102O09|PL00017I22|2820 contigs=104 ver=1 seqid=106810 
GGTCGGACCTGCGGAGCCCAGGATGGTGTTGCTCGAGAGCGAGCAGTTCCTGACGGAGCTGACCAGGCTCTT
CCAGAAGTGCCGCTCGTCGGGCAGCGTGTTCATCACCCTCAAGAAATATGACGGTCGCACCAAACCTATCCC
GAGGAAGAGTTCTGTGGAGGGCCTCGAGCCTGCAGAAAACAAGTGTCTGTTGAGAGCCACGGATGGGAAAAG
GAAGATCAGCACCGTGGTGAGCTCCAAAGAAGTGAACAAGTTTCAGATGGCCTATTCAAATCTACTGAGAGC
CAACATGGACGGGCTGAAGAAGAGGGACAAGAAGAACAAGAGTAAGAAGAGCAAACCAGCACAGTGACAGGC
GTGGCTGCTACCAACCAGCTGCACAAGTGCATTTTTCCTCTGTTTGCTGCTTTCAGCACCTCTGTATGTAAC
TGTTTCCACGGAAGGGTCCTTTAAGAGAGAAGGACTGGGATGGGCATGGGCTAGTTGTGGTAAGACGCCAGT
TTTTGATTTGTGCTGTGTGGCTGGATATTCTTAGATTCCAGCCGTAAGGTTTCTAGTCATCTTTGAGGAGCT
ATGCATCATTAATCTCCAGGCTAGCTGCTTTTTTTCCTACCCTATTTATGACAGTAACTACTAACTCTAGAT
GGTACAGTTACTCAAGTGATTTTTACCTTGTCATGAGATTACTGTAATAGTTTTATTAAAAGTTGTGTTATC
CTACAGGTGGGTTGTTTTTCTTGGTTGTATAATTTAAAACAACAAAAAATGCATCTAGTTATTTTGTATGTC
TGTTGCACATTTGCTCTGTGCCACAGCAACAACCTGTACGATTGGTTTTCTCGTACTATGTGTGTCTGGGAC
TGAACTCAGGTATTTGGGGCTGGGCAGCAAGCATCTTTAATGCCGAGGCCATCTGTCTTCCTGGACCTTATC
TAATCTTATACGATTCCTTCAGCTAGTCTGAGTTCTCATAGCCAAACAGGAGTTTGCTTAAGGACATTAAGA
TAAATATTGGAGAATCATCAAGAATAAAGATCCTGCCTGGCGTGGTGGCATAACCTGTAATCTCCGTGGTCT
GGAGGCAGGGCTGATTTTGAGTTTGAGGCCAGCCTGGGATGCATAGTGAGACCCTGTTCTGCCCTCCCACCC
AGCCACAGAGGCAGAACAGAACACAAGGGATGACATTTGATCTCTGTGCCTTTTTATCTACTAGGAGAATGT
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AAATGTTAGGACATTTTTATGTGCTTAGTGTTTAGGATCAAAGGAAGACAAGTCTGTTTTCTTCTCCAGCTC
CACATAAGGGCTAGTATTGGCAGAACTGCAAATGGAAAACAGCAGATATCTATGAAAACATTTATTATATCA
AAAAGGTAAATTTATACATGAAAACCCGACAAAGCTCAGCTTTGTAGGACAGCTTATTAGAATTTAAAGTTA
AAATGAATGCACAACATTCCATTATTTCAGTATAAGTCCCTGTCCATTTGAACAATACAGCAGCAGTTCTTT
AGGGTCAAAATAGGATTCTGTAGTAGTCATCTCTGTAGCTGTACAGGAACAGCACTGACACCCTGCAAGAGA
AAAGGACAAGCACACCGATGGCAGACTTAGTGGGATAATTTCATAGCTTTGTTTTAATTAAAAATATGATGG
GAGGTTGATCACTAGAAAGACTGCATAAACTTTCTTGGAGCTGTGATTGACAGTTTGCAATTAAGTTCTGAT
GAAGAAACTGCCATTCACCACCAACTTCCTTGATGTCCTTTAGTTAAACAGTGACATAAATGACTGGCATTT
TGACATACACAGCAAAGGTAGTCATTTTTTGTTTTGTTTTTTAATGTCATTTGCTTTTTTTGTGACTGAGTT
TCATGGAACCCGGACTGCCTTCAAACTTGCTTATAAGGCTAAACATGACCTTGGATGCCTGATCTGTCTCTA
CATCCCAAGTTCTAGGATTATAGTTGTATGCCATCATCCCTGACTTAGTTGTGTAAATGTTTTCTGAGGCTT
GGGAGATGGCCCAGTTGGTAAAGTGCATGCCAAGCAAGCACTGAGTTTGGATCCCTAGAAGCAGTGTTAAAA
GCTGGGCAGAGTAGTTCCTGACAGTGTGGCCTTGGACAGGGTAGAGATATGTGTGTCCCCGAAGTCAGTGAT
GCCAGTCAGCCTAGCTCATTGGTGAGCTTCAGGCTCAGAGAGAGACCCTGTCTCAAAAAGAAATGGTGACGA
GGAAAGTGGCATGAACCCCATGTCTCCACATGTCACACACACAATATCCCGATGCTGCGCTCAGGCTCACAG
TGCTACTGACAAGATCCTCACAGTGATTCACAGTCTAGAATTTGTTGACTGTTAACCCTTGACACTCAGTCA
GACCCTTCCCTAAATTTTAACCACATGAAACCTGCTATAACTTACTTCTTTTCAACTTTGATGTTATAAATT
TCATCGCAGACGAGTTTGAGGTATCTTTGCTTTGGCAGGCGTGACAGCAGCTGCTTCACAGTTGTGTTAAAT
GCCTGTTCATCAGCATCCCACTAGGAAAGATGAGACCAGATGTGACAGAGCAGAGCAGCAGGGTTACTGCCT
GACTTTGTGGCTCAGCAGTGTTGGTGATGGGGAGTCTGTGGCTCTTCCTTTGAAGCTTCAATTTTCTTTTGA
GACTACAGGTATCTAGTTAGAGCCTGCTCTGCCTTGCCATAGCCAGGGTATTCGAATGTGACTGTAGATTGC
TTTTCTTGGACATTTCCTGTGTATAGTGGACACTGTTGCCTTTCATGTGTACTCACTGAACTGGATCAAAAA
TCAGTAAACTGC 
 
Amino acid sequence: 
MVLLESEQFLTELTRLFQKCRSSGSVFITLKKYDGRTKPIPRKSSVEGLEPAEN
KCLLRATDGKRKISTVVSSKEVNKFQMAYSNLLRANMDGLKKRDKKNKSKK
SKPAQ 
NCBI accession number: NM_003134 
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7.2 Abbreviations 
# antisera 
A adenosine 
Ago Argonaute 
Amp ampicillin 
APS ammonium persulfate 
AS antisense 
ATP adenosine triphosphate 
attB bacterial attachment site 
bp base pair(s) 
BSA bovine serum albumin 
C cytosine 
c concentration 
dATP deoxyadenosine triphosphate 
DGCR8 DiGeorge syndrome critical region 8 
dH2O distilled H2O 
DMEM Dulbecco's modified Eagle's medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleoside triphosphate 
dNTP deoxynucleoside triphosphate 
ds double-stranded 
DTT 1,4-dithiothreitol 
E. coli Escherichia coli 
ECL enhanced chemiluminescence 
EDTA ethylene-diaminetetraacetic acid 
EtOH ethanol 
FCS fetal calf serum 
fwd forward 
g gravity 
G guanine 
GFP green fluorescent protein 
HEPES N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
hnRNP heterogeneous nuclear ribonucleoproteins 
HRP horseradish peroxidase 
IPTG isopropyl !-D-1-thiogalactopyranoside 
Kan  kanamycin 
kb kilobase pair(s) 
kDa kilodalton 
L1 loop 1 
LB lysogeny broth 
LNK linker 
mA milliampere 
miRNA miRNA 
miRNP miRNA-ribonucleoprotein 
mRNA messenger RNA 
NaOAc sodium acetate 
Ni Nickel 
Ni-NTA Ni2+-nitrilotriacetic acid 
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nm nanometer 
No. number 
nt nucleotide(s) 
OD optical density 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate-buffered saline 
PBST PBS containing 0.1% Tween® 20 
PCI phenol-chloroform-isoamyl alcohol 
PCR polymerase chain reaction 
pH power of hydrogen 
pre-miRNA precursor miRNA 
pri-miRNA primary miRNA 
PTGS post-transcriptional gene silencing 
rDcr recombinant Dicer 
rev reverse 
RISC RNA-induced silencing complex 
RNA ribonucleic acid 
RNAi RNA interference 
RNase ribonuclease 
RT room temperature 
SDS sodium dodecyl sulfate 
SE sense 
siRNA small interfering RNA 
SRP signal recognition particle 
stRNA small temporal RNA 
T thymine 
Ta annealing temperature 
TBE tris-borate electrophoresis buffer 
TE tris-EDTA 
TEMED N, N, N', N'-tetramethylethylenediamine 
Tm melting temperature 
TN tris-sodium chloride 
TRBP trans-activation-responsive RNA-binding protein 
Tris tris-(hydroxymethyl)aminomethane 
tRNA transfer RNA 
TY-MED tryptone-yeast extract medium 
U unit (enzymatic activity) 
U uracil 
UTR untranslated region 
UV ultra-violet 
V Volt 
W Watt 
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7.4 Abstract 
RNA silencing is a recently discovered naturally occurring mechanism to regulate gene 
expression in a wide range of organisms. Key players of RNA silencing are small RNA 
molecules termed microRNAs (miRNAs), which act as post-transcriptional regulators on 
mRNAs to induce inhibition of translation or degradation. The process of how miRNAs 
are generated has been investigated intensely in the last years and many protein factors 
involved have been identified. However, regulation of miRNA biogenesis is still a field of 
research with many open questions. Recent studies have indicated that miR-138 displays 
differential expression of its precursor form in mouse tissues, while the mature miRNA is 
expressed solely in neural tissues. This phenomenon was shown to be due to an unknown 
protein factor inhibiting processing of the precursor to the mature miRNA. Several 
candidate proteins have been identified by chromatography methods of which the 
heterodimer SRP9/14 was the most promising. In this thesis, evaluation of SRP9/14 as a 
putative inhibitor of miRNA biogenesis was performed using two approaches: first, the 
heterodimer was expressed as recombinant protein and tested for its ability to inhibit 
processing of pre-miR-138 in in vitro assays. Second, SRP9/14 was knocked-down in 
HeLa cells using siRNAs followed by testing depleted cell extracts inhibitory activity using 
in vitro processing assays. Both approaches demonstrated that SRP9/14 does not inhibit 
pre-miR-138 maturation and has to be excluded from the list of putative inhibitors.  
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7.5 Zusammenfassung 
RNA Silencing ist ein kürzlich entdeckter, natürlich vorkommender Mechanismus zur 
Regulation von Genexpression in zahlreichen Organismen. Die Schlüsselfunktion des 
RNA Silencing wird von kleinen RNA-Molekülen namens microRNAs (miRNAs) 
getragen, die als post-transkriptionelle Regulatoren auf mRNAs einwirken, um 
Translationsinhibition oder Degradierung zu induzieren. Die Entstehung von miRNAs 
wurde in der Vergangenheit intensiv erforscht, weshalb zahlreiche beteiligte 
Proteinfaktoren bereits identifiziert werden konnten. Die Regulation der miRNA-
Biogenese ist allerdings noch ein Forschungsfeld mit vielen offenen Fragen. Jüngste 
Untersuchungen zeigen, dass die Vorstufe von miR-138 in Mausgeweben differentiell 
exprimiert wird, während die reife miRNA lediglich in Nervengewebe exprimiert wird. Es 
konnte auch gezeigt werden, dass diese Beobachtung auf einen unbekannten 
Proteinfaktor zurückzuführen ist, der die Prozessierung von der Vorstufe zur reifen Form 
blockiert. Einige Kandidaten konnten durch chromatographische Methoden identifiziert 
werden, wobei das Heterodimer SRP9/14 am vielversprechendsten war. In der 
vorliegenden Studie wurde SRP9/14 als potentieller Inhibitor für die miRNA-Biogenese 
mittels zweier Methoden evaluiert: einerseits wurde das Heterodimer als rekombinantes 
Protein exprimiert und auf seine Funktionalität als Inhibitor von miR-138 in in vitro 
Assays getestet. Andererseits wurde die Expression von SRP9/14 in HeLa-Zellen durch 
siRNAs abgeschaltet und die Zellextrakte funktionell auf Vorhandensein des Inhibitors 
getestet. Beide Methoden zeigten, dass es sich bei SRP9/14 nicht um den gesuchten 
Inhibitor handelt.  
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